(State or other jurisdiction of incorporation or organization) | (I.R.S. Employer Identification No.) | |||||||
(Address of principal executive offices) | (Zip code) |
Title of each class | Trading symbol(s) | Name of exchange on which registered | ||||||
☒ | Accelerated filer | ☐ | |||||||||
Non-accelerated filer | ☐ | Smaller reporting company | |||||||||
Emerging growth company |
Class | Outstanding at April 27, 2021 | ||||
Common Stock, $0.01 par value |
Page No. | ||||||||
March 31, 2021 (unaudited) and December 31, 2020 | ||||||||
(unaudited) for the three months ended March 31, 2021 and 2020 | ||||||||
(unaudited) for the three months ended March 31, 2021 and 2020 | ||||||||
(unaudited) for the three months ended March 31, 2021 and 2020 | ||||||||
(unaudited) for the three months ended March 31, 2021 and 2020 | ||||||||
March 31, | December 31, | ||||||||||
2021 | 2020 | ||||||||||
Assets | (unaudited) | ||||||||||
Cash and cash equivalents | $ | $ | |||||||||
Short-term investments | |||||||||||
Accounts receivable, net | |||||||||||
Inventories, net | |||||||||||
Prepaid expenses and other current assets | |||||||||||
Total current assets | |||||||||||
Property and equipment, net | |||||||||||
Goodwill | |||||||||||
Intangible assets, net | |||||||||||
Operating lease right-of-use assets | |||||||||||
Other long-term assets | |||||||||||
Total assets | $ | $ | |||||||||
Liabilities and stockholders' equity | |||||||||||
Accounts payable and accrued expenses | $ | $ | |||||||||
Accrued compensation | |||||||||||
Deferred revenue - current | |||||||||||
Operating lease liabilities - current | |||||||||||
Other taxes payable | |||||||||||
Debt, current | |||||||||||
Other current liabilities | |||||||||||
Total current liabilities | |||||||||||
Deferred income taxes | |||||||||||
Liability for uncertain income tax positions | |||||||||||
Income taxes payable - non-current | |||||||||||
Deferred revenue - non-current | |||||||||||
Operating lease liabilities - non-current | |||||||||||
Debt, non-current | |||||||||||
Other long-term liabilities | |||||||||||
Total liabilities | |||||||||||
Commitments and contingencies | |||||||||||
Stockholders' equity: | |||||||||||
Preferred stock: par value $ | |||||||||||
Common stock: par value $ | |||||||||||
Additional paid-in capital | |||||||||||
Retained earnings | |||||||||||
Accumulated other comprehensive loss | ( | ( | |||||||||
Total stockholders’ equity | |||||||||||
Total liabilities and stockholders' equity | $ | $ |
Three Months Ended | ||||||||||||||
March 31, | ||||||||||||||
2021 | 2020 | |||||||||||||
Net sales: | ||||||||||||||
Product | $ | $ | ||||||||||||
Software maintenance | ||||||||||||||
Total net sales | ||||||||||||||
Cost of sales: | ||||||||||||||
Product | ||||||||||||||
Software maintenance | ||||||||||||||
Total cost of sales | ||||||||||||||
Gross profit | ||||||||||||||
Operating expenses: | ||||||||||||||
Sales and marketing | ||||||||||||||
Research and development | ||||||||||||||
General and administrative | ||||||||||||||
Total operating expenses | ||||||||||||||
Gain on sale of business/assets | ||||||||||||||
Operating income | ||||||||||||||
Other (expense) income | ( | |||||||||||||
Income before income taxes | ||||||||||||||
(Benefit) provision for income taxes | ( | |||||||||||||
Net income | $ | $ | ||||||||||||
Basic earnings per share | $ | |||||||||||||
Weighted average shares outstanding - basic | ||||||||||||||
Diluted earnings per share | $ | $ | ||||||||||||
Weighted average shares outstanding - diluted | ||||||||||||||
Dividends declared per share | $ | $ |
Three Months Ended | ||||||||||||||
March 31, | ||||||||||||||
2021 | 2020 | |||||||||||||
Net income | $ | $ | ||||||||||||
Other comprehensive income (loss), before tax and net of reclassification adjustments: | ||||||||||||||
Foreign currency translation adjustment | ( | ( | ||||||||||||
Unrealized loss on securities available-for-sale | ( | ( | ||||||||||||
Unrealized gain (loss) on derivative instruments | ( | |||||||||||||
Other comprehensive income (loss), before tax | ( | |||||||||||||
Tax expense related to items of other comprehensive income | ||||||||||||||
Other comprehensive income (loss), net of tax | ( | |||||||||||||
Comprehensive income | $ | $ |
Three Months Ended | ||||||||||||||
March 31, | ||||||||||||||
2021 | 2020 | |||||||||||||
Cash flow from operating activities: | ||||||||||||||
Net income | $ | $ | ||||||||||||
Adjustments to reconcile net income to net cash provided by operating activities: | ||||||||||||||
Disposal gain on sale of business/assets | ( | |||||||||||||
Depreciation and amortization | ||||||||||||||
Stock-based compensation | ||||||||||||||
Loss from equity-method investees | ||||||||||||||
Deferred income taxes | ( | ( | ||||||||||||
Changes in operating assets and liabilities, net of divestitures | ( | |||||||||||||
Net cash provided by operating activities | ||||||||||||||
Cash flow from investing activities: | ||||||||||||||
Capital expenditures | ( | ( | ||||||||||||
Proceeds from sale of business, net of cash divested | ||||||||||||||
Capitalization of internally developed software | ( | ( | ||||||||||||
Additions to other intangibles | ( | ( | ||||||||||||
Payments to acquire equity-method investments | ( | |||||||||||||
Purchases of short-term investments | ( | |||||||||||||
Sales and maturities of short-term investments | ||||||||||||||
Net cash provided by investing activities | ||||||||||||||
Cash flow from financing activities: | ||||||||||||||
Payments on term loan | ( | |||||||||||||
Proceeds from issuance of common stock | ||||||||||||||
Repurchase of common stock | ( | |||||||||||||
Dividends paid | ( | ( | ||||||||||||
Net cash used in financing activities | ( | ( | ||||||||||||
Effect of exchange rate changes on cash | ( | ( | ||||||||||||
Net change in cash and cash equivalents | ||||||||||||||
Cash and cash equivalents at beginning of period | ||||||||||||||
Cash and cash equivalents at end of period | $ | $ |
March 31, 2021 | ||||||||||||||||||||||||||||||||||||||
Common Stock Shares | Common Stock Amount | Additional-Paid in Capital | Retained Earnings | Accumulated Other Comprehensive Income/(Loss) | Total Stockholders' Equity | |||||||||||||||||||||||||||||||||
Balance at December 31, 2020 | $ | $ | $ | $ | ( | $ | ||||||||||||||||||||||||||||||||
Net income | — | — | — | — | ||||||||||||||||||||||||||||||||||
Other comprehensive income, net of tax | — | — | — | — | ||||||||||||||||||||||||||||||||||
Issuance of common stock under employee plans | — | — | ||||||||||||||||||||||||||||||||||||
Stock-based compensation | — | — | — | — | ||||||||||||||||||||||||||||||||||
Dividends paid (1) | — | — | — | ( | — | ( | ||||||||||||||||||||||||||||||||
Balance at March 31, 2021 | $ | $ | $ | $ | ( | $ |
March 31, 2020 | ||||||||||||||||||||||||||||||||||||||
Common Stock Shares | Common Stock Amount | Additional-Paid in Capital | Retained Earnings | Accumulated Other Comprehensive Income/(Loss) | Total Stockholders' Equity | |||||||||||||||||||||||||||||||||
Balance at December 31, 2019 | $ | $ | $ | $ | ( | $ | ||||||||||||||||||||||||||||||||
Net income | — | — | — | — | ||||||||||||||||||||||||||||||||||
Other comprehensive loss, net of tax | — | — | — | — | ( | ( | ||||||||||||||||||||||||||||||||
Issuance of common stock under employee plans | — | — | ||||||||||||||||||||||||||||||||||||
Stock-based compensation | — | — | — | — | ||||||||||||||||||||||||||||||||||
Repurchase of common stock | ( | ( | ( | ( | — | ( | ||||||||||||||||||||||||||||||||
Dividends paid (1) | — | — | — | ( | — | ( | ||||||||||||||||||||||||||||||||
Balance at March 31, 2020 | $ | $ | $ | $ | ( | $ |
Cash | $ | ||||
Accounts receivable, net | |||||
Prepaid and other current assets | |||||
Goodwill | |||||
Other non-current assets | |||||
Total assets | $ | ||||
Deferred revenue | $ | ||||
Other current liabilities | |||||
Cumulative translation adjustment | ( | ||||
Total liabilities and stockholders' equity | $ | ||||
Total assets divested, net (including cash) | $ |
Three Months Ended March 31, | ||||||||
(Unaudited) | ||||||||
2021 | 2020 | |||||||
Interest income | $ | $ | ||||||
Interest expense | ( | ( | ||||||
Loss from equity-method investments | ( | ( | ||||||
Net foreign exchange loss | ( | ( | ||||||
Other | ( | |||||||
Other (expense) income, net | $ | ( | $ | |||||
As of March 31, 2021 | As of December 31, | |||||||
(unaudited) | 2020 | |||||||
Income taxes payable - current | $ | $ | ||||||
Hedge payable - current | ||||||||
Other | ||||||||
Total | $ | $ |
Three Months Ended March 31, | ||||||||||||||
(In thousands) | ||||||||||||||
(Unaudited) | ||||||||||||||
2021 | 2020 | |||||||||||||
Weighted average shares outstanding-basic | ||||||||||||||
Plus: Common share equivalents | ||||||||||||||
RSUs | ||||||||||||||
Weighted average shares outstanding-diluted |
Three Months Ended March 31, | ||||||||||||||||||||||||||
(In thousands) | (Unaudited) | |||||||||||||||||||||||||
2021 | 2020 | |||||||||||||||||||||||||
Net sales: | Point-in-Time(1) | Over Time | Total | Point-in-Time(1) | Over Time | Total | ||||||||||||||||||||
Americas | $ | $ | $ | $ | $ | $ | ||||||||||||||||||||
EMEA | ||||||||||||||||||||||||||
APAC | ||||||||||||||||||||||||||
Total net sales(1) | $ | $ | $ | $ | $ | $ | ||||||||||||||||||||
(1): Net sales contains hedging gains and losses, which do not represent revenues recognized from customers. See Note 5 - Derivative instruments and hedging activities of Notes to Consolidated Financial Statements for more information on the impact of our hedging activities on our results of operations |
Amount | |||||
(In thousands) | |||||
Deferred Revenue at December 31, 2020 | $ | ||||
Deferral of revenue billed in current period, net of recognition | |||||
Recognition of revenue deferred in prior periods | ( | ||||
Foreign currency translation impact | ( | ||||
Balance as of March 31, 2021 (unaudited) | $ |
As of March 31, 2021 | ||||||||||||||||||||||||||
(In thousands) | (Unaudited) | |||||||||||||||||||||||||
Gross | Gross | |||||||||||||||||||||||||
Adjusted Cost | Unrealized Gain | Unrealized Loss | Fair Value | |||||||||||||||||||||||
Corporate bonds | $ | $ | $ | $ | ||||||||||||||||||||||
Total Short-term investments | $ | $ | $ | $ |
(In thousands) | As of December 31, 2020 | |||||||||||||||||||||||||
Gross | Gross | |||||||||||||||||||||||||
Adjusted Cost | Unrealized Gain | Unrealized Loss | Fair Value | |||||||||||||||||||||||
Corporate bonds | $ | $ | $ | ( | $ | |||||||||||||||||||||
Total Short-term investments | $ | $ | $ | ( | $ |
As of March 31, 2021 | ||||||||||||||
(Unaudited) | ||||||||||||||
(In thousands) | Adjusted Cost | Fair Value | ||||||||||||
Due in less than 1 year | $ | $ | ||||||||||||
Total available-for-sale debt securities | $ | $ | ||||||||||||
Due in less than 1 year | Adjusted Cost | Fair Value | ||||||||||||
Corporate bonds | $ | $ | ||||||||||||
Total available-for-sale debt securities | $ | $ | ||||||||||||
Fair Value Measurements at Reporting Date Using | ||||||||||||||||||||||||||
(In thousands) | (Unaudited) | |||||||||||||||||||||||||
Description | March 31, 2021 | Quoted Prices in Active Markets for Identical Assets (Level 1) | Significant Other Observable Inputs (Level 2) | Significant Unobservable Inputs (Level 3) | ||||||||||||||||||||||
Assets | ||||||||||||||||||||||||||
Cash and cash equivalents available for sale: | ||||||||||||||||||||||||||
Money Market Funds | $ | $ | $ | $ | ||||||||||||||||||||||
Short-term investments available for sale: | ||||||||||||||||||||||||||
Corporate notes and bonds | ||||||||||||||||||||||||||
Derivatives | ||||||||||||||||||||||||||
Total Assets | $ | $ | $ | $ | ||||||||||||||||||||||
Liabilities | ||||||||||||||||||||||||||
Derivatives | $ | ( | $ | $ | ( | $ | ||||||||||||||||||||
Total Liabilities | $ | ( | $ | $ | ( | $ |
(In thousands) | Fair Value Measurements at Reporting Date Using | |||||||||||||||||||||||||
Description | December 31, 2020 | Quoted Prices in Active Markets for Identical Assets (Level 1) | Significant Other Observable Inputs (Level 2) | Significant Unobservable Inputs (Level 3) | ||||||||||||||||||||||
Assets | ||||||||||||||||||||||||||
Cash and cash equivalents available for sale: | ||||||||||||||||||||||||||
Money Market Funds | $ | $ | $ | $ | ||||||||||||||||||||||
Short-term investments available for sale: | ||||||||||||||||||||||||||
Corporate notes and bonds | ||||||||||||||||||||||||||
Derivatives | ||||||||||||||||||||||||||
Total Assets | $ | $ | $ | $ | ||||||||||||||||||||||
Liabilities | ||||||||||||||||||||||||||
Derivatives | $ | ( | $ | $ | ( | $ | ||||||||||||||||||||
Total Liabilities | $ | ( | $ | $ | ( | $ |
(In thousands) | US Dollar Equivalent | |||||||||||||
As of March 31, 2021 | As of December 31, | |||||||||||||
(Unaudited) | 2020 | |||||||||||||
Chinese yuan | $ | $ | ||||||||||||
Euro | ||||||||||||||
Japanese yen | ||||||||||||||
Hungarian forint | ||||||||||||||
British pound | ||||||||||||||
Malaysian ringgit | ||||||||||||||
Korean won | ||||||||||||||
Total forward contracts notional amount | $ | $ |
Asset Derivatives | ||||||||||||||||||||
March 31, 2021 | December 31, 2020 | |||||||||||||||||||
(Unaudited) | ||||||||||||||||||||
(In thousands) | Balance Sheet Location | Fair Value | Fair Value | |||||||||||||||||
Derivatives designated as hedging instruments | ||||||||||||||||||||
Foreign exchange contracts - ST forwards | Prepaid expenses and other current assets | $ | $ | |||||||||||||||||
Foreign exchange contracts - LT forwards | Other long-term assets | |||||||||||||||||||
Total derivatives designated as hedging instruments | $ | $ | ||||||||||||||||||
Derivatives not designated as hedging instruments | ||||||||||||||||||||
Foreign exchange contracts - ST forwards | Prepaid expenses and other current assets | $ | $ | |||||||||||||||||
Total derivatives not designated as hedging instruments | $ | $ | ||||||||||||||||||
Total derivatives | $ | $ |
Liability Derivatives | ||||||||||||||||||||
March 31, 2021 | December 31, 2020 | |||||||||||||||||||
(Unaudited) | ||||||||||||||||||||
(In thousands) | Balance Sheet Location | Fair Value | Fair Value | |||||||||||||||||
Derivatives designated as hedging instruments | ||||||||||||||||||||
Foreign exchange contracts - ST forwards | Other current liabilities | $ | ( | $ | ( | |||||||||||||||
Foreign exchange contracts - LT forwards | Other long-term liabilities | ( | ( | |||||||||||||||||
Total derivatives designated as hedging instruments | $ | ( | $ | ( | ||||||||||||||||
Derivatives not designated as hedging instruments | ||||||||||||||||||||
Foreign exchange contracts - ST forwards | Other current liabilities | $ | ( | $ | ( | |||||||||||||||
Total derivatives not designated as hedging instruments | $ | ( | $ | ( | ||||||||||||||||
Total derivatives | $ | ( | $ | ( |
March 31, 2021 | ||||||||||||||||||||
(In thousands) | ||||||||||||||||||||
(Unaudited) | ||||||||||||||||||||
Derivatives in Cash Flow Hedging Relationship | Gain or (Loss) Recognized in OCI on Derivative | Location of Gain or (Loss) Reclassified from Accumulated OCI into Income | Gain or (Loss) Reclassified from Accumulated OCI into Income | |||||||||||||||||
Foreign exchange contracts - forwards | $ | Net sales | $ | ( | ||||||||||||||||
Foreign exchange contracts - forwards | ( | Cost of sales | ( | |||||||||||||||||
Foreign exchange contracts - forwards | ( | Operating expenses | ( | |||||||||||||||||
Total | $ | $ | ( |
March 31, 2020 | ||||||||||||||||||||
(In thousands) | ||||||||||||||||||||
(Unaudited) | ||||||||||||||||||||
Derivatives in Cash Flow Hedging Relationship | Gain or (Loss) Recognized in OCI on Derivative | Location of Gain or (Loss) Reclassified from Accumulated OCI into Income | Gain or (Loss) Reclassified from Accumulated OCI into Income | |||||||||||||||||
Foreign exchange contracts - forwards | $ | Net sales | $ | |||||||||||||||||
Foreign exchange contracts - forwards | ( | Cost of sales | ( | |||||||||||||||||
Foreign exchange contracts - forwards | ( | Operating expenses | ( | |||||||||||||||||
Total | $ | ( | $ |
(In thousands) | ||||||||||||||||||||
Derivatives not Designated as Hedging Instruments | Location of Gain (Loss) Recognized in Income | Amount of Gain (Loss) Recognized in Income | Amount of Gain (Loss) Recognized in Income | |||||||||||||||||
March 31, 2021 | March 31, 2020 | |||||||||||||||||||
(Unaudited) | (Unaudited) | |||||||||||||||||||
Foreign exchange contracts - forwards | Other (expense) income | $ | ( | |||||||||||||||||
Total | $ | ( | $ |
March 31, 2021 | December 31, | |||||||||||||
(In thousands) | (Unaudited) | 2020 | ||||||||||||
Raw materials | $ | $ | ||||||||||||
Work-in-process | ||||||||||||||
Finished goods | ||||||||||||||
Total | $ | $ |
March 31, 2021 | ||||||||||||||||||||||||||||||||||||||
(In thousands) | (Unaudited) | December 31, 2020 | ||||||||||||||||||||||||||||||||||||
Gross Carrying Amount | Accumulated Amortization | Net Carrying Amount | Gross Carrying Amount | Accumulated Amortization | Net Carrying Amount | |||||||||||||||||||||||||||||||||
Capitalized software development costs | $ | $ | ( | $ | $ | $ | ( | $ | ||||||||||||||||||||||||||||||
Acquired technology | ( | ( | ||||||||||||||||||||||||||||||||||||
Customer relationships | ( | ( | ||||||||||||||||||||||||||||||||||||
Patents | ( | ( | ||||||||||||||||||||||||||||||||||||
Other | ( | ( | ||||||||||||||||||||||||||||||||||||
Total | $ | $ | ( | $ | $ | $ | ( | $ |
Amount | |||||
(In thousands) | |||||
Balance as of December 31, 2020 | $ | ||||
Measurement period adjustment | ( | ||||
Foreign currency translation impact | ( | ||||
Balance as of March 31, 2021 (unaudited) | $ |
(In thousands) | March 31, 2021 | March 31, 2020 | ||||||
Operating Lease Cost (a) | $ | $ | ||||||
(a) includes variable and short-term lease costs |
(In thousands) | ||||||||
Years ending December 31, | Operating Leases | |||||||
2021 (Excluding the three months ended March 31, 2021) | $ | |||||||
2022 | ||||||||
2023 | ||||||||
2024 | ||||||||
2025 | ||||||||
Thereafter | ||||||||
Total future minimum lease payments | ||||||||
Less imputed interest | ( | |||||||
Total | $ |
March 31, 2021 | ||||||||||||||||||||||||||
(Unaudited) | ||||||||||||||||||||||||||
(In thousands) | Currency translation adjustment | Investments | Derivative instruments | Accumulated other comprehensive income/(loss) | ||||||||||||||||||||||
Balance as of December 31, 2020 | $ | ( | $ | ( | ( | $ | ( | |||||||||||||||||||
Current-period other comprehensive (loss) income | ( | ( | ||||||||||||||||||||||||
Reclassified from accumulated OCI into income | ||||||||||||||||||||||||||
Income tax (benefit) expense | ( | |||||||||||||||||||||||||
Balance as of March 31, 2021 | $ | ( | $ | ( | $ | ( | $ | ( |
March 31, 2020 | ||||||||||||||||||||||||||
(Unaudited) | ||||||||||||||||||||||||||
(In thousands) | Currency translation adjustment | Investments | Derivative instruments | Accumulated other comprehensive income/(loss) | ||||||||||||||||||||||
Balance as of December 31, 2019 | $ | ( | $ | ( | $ | ( | ||||||||||||||||||||
Current-period other comprehensive (loss) income | ( | ( | ( | |||||||||||||||||||||||
Reclassified from accumulated OCI into income | ( | ( | ||||||||||||||||||||||||
Income tax (benefit) expense | ( | |||||||||||||||||||||||||
Balance as of March 31, 2020 | $ | ( | $ | ( | $ | $ | ( |
Three Months Ended | ||||||||
(unaudited) | ||||||||
March 31, 2021 | March 31, 2020 | |||||||
Number of simulations | ||||||||
Expected volatility | ||||||||
Expected life in years | ||||||||
Risk-free interest rate | ||||||||
Dividend yield |
United States | China(1) | Rest of the World | Total | |||||||||||
(in millions) | ||||||||||||||
Net sales: | ||||||||||||||
Three months ended March 31, 2021 | $ | $ | $ | $ | ||||||||||
Three months ended March 31, 2020 | $ | $ | $ | $ | ||||||||||
(1): Includes Mainland China and the Hong Kong Special Administrative Region |
March 31, | December 31, | |||||||
2021 | 2020 | |||||||
Secured | ||||||||
2020 term loan (effective interest rate of | $ | $ | ||||||
Total Debt | ||||||||
Less: Unamortized debt issuance costs | ( | ( | ||||||
Less: Current Portion of Total Debt | ( | ( | ||||||
Total Debt, non-current | $ | $ |
Three Months Ended March 31, | ||||||||||||||
(In thousands) | (Unaudited) | |||||||||||||
2021 | 2020 | |||||||||||||
Balance at the beginning of the period | $ | $ | ||||||||||||
Accruals for warranties issued during the period | ||||||||||||||
Accruals related to pre-existing warranties | ||||||||||||||
Settlements made (in cash or in kind) during the period | ( | ( | ||||||||||||
Balance at the end of the period | $ | $ |
Three Months Ended March 31, | ||||||||||||||
(In thousands) | (Unaudited) | |||||||||||||
2021 | 2020 | |||||||||||||
Cost of sales | $ | $ | ||||||||||||
Research and development | ||||||||||||||
Sales and marketing | ||||||||||||||
General and administrative | ||||||||||||||
Total restructuring and other related costs | $ | $ |
Restructuring Liability | |||||
(in thousands) | |||||
Balance as of December 31, 2020 | $ | ||||
Income statement expense | |||||
Cash payments | ( | ||||
Balance as of March 31, 2021 | $ |
July 2, 2020 | |||||
Consideration Transferred | $ | ||||
Cash | |||||
Intangible assets | |||||
Goodwill | |||||
Contract assets | |||||
Deferred revenue | ( | ||||
Accounts receivable | |||||
Other assets and liabilities | ( | ||||
Deferred tax liabilities | ( | ||||
Net assets acquired | $ |
Estimated Fair Value | Estimated Useful Lives (in years) | |||||||
Customer relationships | $ | |||||||
Developed technology | ||||||||
In-process research and development (IPR&D) | Indefinite | |||||||
Other intangibles | ||||||||
Total | $ |
Three Months Ended March 31, | |||||
2020 | |||||
(in thousands) | (unaudited) | ||||
Net sales | $ | ||||
Net income | $ |
Three Months Ended March 31, | ||||||||||||||
(Unaudited) | ||||||||||||||
2021 | 2020 | |||||||||||||
Net sales: | ||||||||||||||
Americas | 37.8 | % | 40.4 | % | ||||||||||
EMEA | 25.5 | 28.0 | ||||||||||||
APAC | 36.7 | 31.6 | ||||||||||||
Total net sales | 100.0 | 100.0 | ||||||||||||
Cost of sales | 28.5 | 27.1 | ||||||||||||
Gross profit | 71.5 | 72.9 | ||||||||||||
Operating expenses: | ||||||||||||||
Sales and marketing | 34.8 | 37.4 | ||||||||||||
Research and development | 23.9 | 23.1 | ||||||||||||
General and administrative | 10.0 | 8.5 | ||||||||||||
Total operating expenses | 68.7 | 69.0 | ||||||||||||
Gain on sale of business/assets | — | 51.6 | ||||||||||||
Operating income | 2.8 | 55.5 | ||||||||||||
Other (expense) income: | (1.5) | 0.2 | ||||||||||||
Income before income taxes | 1.3 | 55.7 | ||||||||||||
(Benefit) Provision for income taxes | — | 12.8 | ||||||||||||
Net income | 1.3 | % | 42.9 | % |
Three Months Ended March 31, | ||||||||||||||||||||||||||
(Unaudited) | ||||||||||||||||||||||||||
Change | ||||||||||||||||||||||||||
(In millions) | 2021 | 2020 | Dollars | Percentage | ||||||||||||||||||||||
Product sales | $ | 295.1 | $ | 274.0 | 21.1 | 8% | ||||||||||||||||||||
Software maintenance sales | 40.1 | 35.4 | 4.7 | 13% | ||||||||||||||||||||||
Total net sales | $ | 335.2 | $ | 309.4 | 25.8 | 8% |
Three Months Ended March 31, | ||||||||||||||||||||||||||
(Unaudited) | ||||||||||||||||||||||||||
Change | ||||||||||||||||||||||||||
(In millions) | 2021 | 2020 | Dollars | Percentage | ||||||||||||||||||||||
Americas | $ | 126.7 | $ | 125.0 | 1.7 | 1% | ||||||||||||||||||||
Percentage of total net sales | 37.8 | % | 40.4 | % | ||||||||||||||||||||||
EMEA | $ | 85.5 | $ | 86.7 | (1.2) | (1)% | ||||||||||||||||||||
Percentage of total net sales | 25.5 | % | 28.0 | % | ||||||||||||||||||||||
APAC | $ | 122.9 | $ | 97.6 | 25.3 | 26% | ||||||||||||||||||||
Percentage of total net sales | 36.7 | % | 31.6 | % | ||||||||||||||||||||||
Three Months Ended March 31, 2020 | Change in Constant Dollars | Impact of changes in foreign currency exchange rates on net sales | Three Months Ended March 31, 2021 | |||||||||||||||||||||||||||||||||||
(In millions) | GAAP Net Sales | Dollars | Percentage | Dollars | Percentage | GAAP Net Sales | ||||||||||||||||||||||||||||||||
Americas | $ | 125.0 | 1.7 | 1.4% | — | —% | $ | 126.7 | ||||||||||||||||||||||||||||||
EMEA | $ | 86.7 | (4.2) | (4.8)% | 2.9 | 3.4% | $ | 85.5 | ||||||||||||||||||||||||||||||
APAC | $ | 97.6 | 21.6 | 22.1% | 3.7 | 3.8% | $ | 122.9 | ||||||||||||||||||||||||||||||
Total net sales | $ | 309.4 | 19.1 | 6.2% | 6.7 | 2.3% | $ | 335.2 |
Three Months Ended March 31, | ||||||||||||||
(Unaudited) | ||||||||||||||
(In millions) | 2021 | 2020 | ||||||||||||
Gross Profit | $239.8 | $225.6 | ||||||||||||
% change compared with prior period | 6.3% | |||||||||||||
Gross Profit as a percentage of net sales | 71.5% | 72.9% | ||||||||||||
Three Months Ended | |||||
(Unaudited) | |||||
March 31, 2020 | 72.9 | % | |||
Impact of amortization of acquired intangibles and other purchase accounting adjustments | (1.4) | % | |||
Impact of changes related to recently acquired/divested businesses | (0.4) | % | |||
Impact of increases in outbound freight and other logistics costs due to COVID-19 | (0.7) | % | |||
Impact of changes in sales mix and sales price | 0.6 | % | |||
Impact of changes in foreign currency exchange rates | 0.5 | % | |||
March 31, 2021 | 71.5 | % |
Three Months Ended March 31, | ||||||||||||||||||||
(Unaudited) | ||||||||||||||||||||
(In thousands) | 2021 | 2020 | Change | |||||||||||||||||
Sales and marketing | $ | 116,783 | $ | 115,746 | 1% | |||||||||||||||
Percentage of total net sales | 35% | 37% | ||||||||||||||||||
Research and development | $ | 80,086 | $ | 71,621 | 12% | |||||||||||||||
Percentage of total net sales | 24% | 23% | ||||||||||||||||||
General and administrative | $ | 33,358 | $ | 26,180 | 27% | |||||||||||||||
Percentage of total net sales | 10% | 8% | ||||||||||||||||||
Total operating expenses | $ | 230,227 | $ | 213,547 | 8% | |||||||||||||||
Percentage of total net sales | 69% | 69% | ||||||||||||||||||
Three Months Ended March 31, | ||||||||
(Unaudited) | ||||||||
Effective tax rate at March 31, 2020 | 23 | % | ||||||
Employee share-based compensation and other discrete items | (22) | % | ||||||
Gain on sale of AWR business | (4) | % | ||||||
Enhanced deduction for certain research and development expenses | (2) | % | ||||||
Foreign taxes greater (less) than federal statutory rate | (1) | % | ||||||
Nondeductible acquisition costs | 1 | % | ||||||
Change in unrecognized tax benefits | 1 | % | ||||||
Global intangible low-taxed income inclusion ("GILTI") | 3 | % | ||||||
Effective tax rate at March 31, 2021 | (1) | % |
Three Months Ended March 31, | ||||||||||||||
(In thousands) | (Unaudited) | |||||||||||||
2021 | 2020 | |||||||||||||
Stock-based compensation | ||||||||||||||
Cost of sales | $ | 1,113 | $ | 804 | ||||||||||
Sales and marketing | 5,696 | 5,175 | ||||||||||||
Research and development | 5,714 | 3,520 | ||||||||||||
General and administrative | 4,666 | 2,603 | ||||||||||||
Provision for income taxes | (3,324) | (1,502) | ||||||||||||
Total | $ | 13,865 | $ | 10,600 |
Three Months Ended March 31, | ||||||||||||||
(In thousands) | (Unaudited) | |||||||||||||
2021 | 2020 | |||||||||||||
Amortization of acquisition-related intangibles | ||||||||||||||
Net sales | $ | 813 | $ | — | ||||||||||
Cost of sales | 4,272 | 746 | ||||||||||||
Sales and marketing | 2,171 | 486 | ||||||||||||
Research and development | — | 28 | ||||||||||||
Other (expense) income | 394 | 124 | ||||||||||||
Provision for income taxes | (975) | (157) | ||||||||||||
Total | $ | 6,675 | $ | 1,227 |
Three Months Ended March 31, | ||||||||||||||
(In thousands) | (Unaudited) | |||||||||||||
2021 | 2020 | |||||||||||||
Acquisition transaction costs, restructuring charges and other(1)(2) | ||||||||||||||
Cost of sales | $ | 75 | $ | 20 | ||||||||||
Sales and marketing | 4,648 | 6,373 | ||||||||||||
Research and development | 488 | 4,669 | ||||||||||||
General and administrative | 5,666 | (1,014) | ||||||||||||
Gain on sale of business/assets(1) | — | (159,753) | ||||||||||||
Other (expense) income(2) | 3,725 | 128 | ||||||||||||
Provision for income taxes | (2,883) | 34,754 | ||||||||||||
Total | $ | 11,719 | $ | (114,823) | ||||||||||
(1): During the first quarter of 2020, we recognized a gain of approximately $160 million related to the divestiture of AWR, presented within "Gain on sale of business/assets". | ||||||||||||||
(2): During the first quarter of 2021, we recognized a $3.5 million impairment loss related to one of our equity-method investments. |
Three Months Ended March 31, | ||||||||||||||
(Unaudited) | ||||||||||||||
(In thousands) | 2021 | 2020 | ||||||||||||
Capitalization and amortization of internally developed software costs | ||||||||||||||
Cost of sales | $ | 6,874 | $ | 7,082 | ||||||||||
Research and development | (226) | (1,915) | ||||||||||||
Provision for income taxes | (1,396) | (1,085) | ||||||||||||
Total | $ | 5,252 | $ | 4,082 |
Domestic | International | Total | |||||||||
Cash and cash equivalents | $109.1 | $157.7 | $266.7 | ||||||||
41% | 59% | ||||||||||
Short-term investments | $28.1 | $4.0 | $32.2 | ||||||||
87% | 13% | ||||||||||
Total cash, cash equivalents and short-term investments | $137.2 | $161.7 | $298.9 | ||||||||
46% | 54% |
March 31, 2021 | December 31, | Increase/ | ||||||||||||||||||
(In thousands) | (unaudited) | 2020 | (Decrease) | |||||||||||||||||
Working capital | $ | 473,389 | $ | 467,655 | $ | 5,734 | ||||||||||||||
Cash and cash equivalents (1) | 266,712 | 260,232 | 6,480 | |||||||||||||||||
Short-term investments (1) | 32,171 | 59,923 | (27,752) | |||||||||||||||||
Total cash, cash equivalents and short-term investments | $ | 298,883 | $ | 320,155 | $ | (21,272) | ||||||||||||||
(1) Included in working capital |
Three Months Ended March 31, | ||||||||||||||
(In thousands) | (unaudited) | |||||||||||||
2021 | 2020 | |||||||||||||
Cash provided by operating activities | $ | 29,841 | $ | 43,620 | ||||||||||
Cash provided by investing activities | 6,393 | 49,626 | ||||||||||||
Cash used in financing activities | (28,218) | (31,532) | ||||||||||||
Effect of exchange rate changes on cash | (1,536) | (1,889) | ||||||||||||
Net change in cash and cash equivalents | 6,480 | 59,825 | ||||||||||||
Cash and cash equivalents at beginning of period | 260,232 | 194,616 | ||||||||||||
Cash and cash equivalents at end of period | $ | 266,712 | $ | 254,441 |
Period | Total number of shares purchased | Average price paid per share | Total number of shares purchased as part of publicly announced plans or programs | Maximum number of shares that may yet be purchased under the plans or programs (1) | ||||||||||||||||||||||
January 1, 2021 to January 31, 2021 | — | $ | — | — | 1,609,943 | |||||||||||||||||||||
February 1, 2021 to February 28, 2021 | — | $ | — | — | 1,609,943 | |||||||||||||||||||||
March 1, 2021 to March 31, 2021 | — | $ | — | — | 1,609,943 | |||||||||||||||||||||
Total | — | $ | — | — | 1,609,943 | |||||||||||||||||||||
(1) On April 21, 2010, our Board of Directors authorized a program to repurchase shares of our common stock from time to time, depending on market conditions and other factors. The Board amended such program several times over the years to increase the number of shares that may be purchased under the program. Most recently, on October 23, 2019, our Board amended the program to increase the number of shares that may be repurchased by 3,000,000 shares. At March 31, 2021, there were 1,609,943 shares remaining available for repurchase under the stock repurchase program. This program does not have an expiration date nor does it obligate the Company to acquire any specific number of shares. | ||||||||||||||||||||||||||
EXHIBITS | |||||
101.INS* | Inline XBRL Instance Document | ||||
101.SCH* | Inline XBRL Taxonomy Extension Schema Document | ||||
101.CAL* | Inline XBRL Taxonomy Extension Calculation Linkbase Document | ||||
101.DEF* | Inline XBRL Taxonomy Extension Definition Linkbase Document | ||||
101.LAB* | Inline XBRL Taxonomy Extension Label Linkbase Document | ||||
101.PRE* | Inline XBRL Taxonomy Extension Presentation Linkbase Document | ||||
104* | Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101) | ||||
(1) | Incorporated by reference to the same-numbered exhibit filed with the Company’s Form 10-K for the fiscal year ended December 31, 2013 filed on February 20, 2014 (File No. 000-25426). | ||||
(2) | Incorporated by reference to Exhibit 3.1 filed with the Company’s Form 8-K on January 28, 2019 (File No. 000-25426). | ||||
(3) | Incorporated by reference to Exhibit 10.36 filed with the Company's Form 10-K for the fiscal year ended December 31, 2020. | ||||
(4) | Incorporated by reference to Exhibit 10.37 filed with the Company's Form 10-K for the fiscal year ended December 31, 2020. | ||||
(5) | Incorporated by reference to Exhibit 10.38 filed with the Company's Form 10-K for the fiscal year ended December 31, 2020. | ||||
The exhibits required to be filed pursuant to the requirements of Item 601 of Regulation S-K are set forth in the Exhibit Index list noted above and are incorporated herein by reference. | |||||
* | Filed herewith | ||||
** | Furnished herewith | ||||
# | Management Contract or Compensatory Plan or Arrangement | ||||
NATIONAL INSTRUMENTS CORPORATION | ||
By: /s/ Karen Rapp | ||
Karen Rapp | ||
EVP, Chief Financial Officer | ||
(Principal Financial Officer) |
By: | /s/ Eric Starkloff | ||||
Eric Starkloff | |||||
Chief Executive Officer |
By: | /s/ Karen Rapp | ||||
Karen Rapp | |||||
Chief Financial Officer |
By: /s/ Eric Starkloff | ||
Eric Starkloff | ||
Chief Executive Officer | ||
Date: May 3, 2021 |
By: /s/ Karen Rapp | ||
Karen Rapp | ||
Chief Financial Officer | ||
Date: May 3, 2021 |
Consolidated Balance Sheets (Parenthetical) - $ / shares |
Mar. 31, 2021 |
Dec. 31, 2020 |
---|---|---|
Statement of Financial Position [Abstract] | ||
Preferred stock, par value per share (in usd per share) | $ 0.01 | $ 0.01 |
Preferred stock, authorized (in shares) | 5,000,000 | 5,000,000 |
Preferred stock, issued (in shares) | 0 | 0 |
Preferred stock, outstanding (in shares) | 0 | 0 |
Common stock, par value per share (in usd per share) | $ 0.01 | $ 0.01 |
Common stock, authorized (in shares) | 360,000,000 | 360,000,000 |
Common stock, issued (in shares) | 131,607,036 | 131,246,615 |
Common stock, outstanding (in shares) | 131,607,036 | 131,246,615 |
Consolidated Statements Of Comprehensive Income - USD ($) $ in Thousands |
3 Months Ended | |
---|---|---|
Mar. 31, 2021 |
Mar. 31, 2020 |
|
Statement of Comprehensive Income [Abstract] | ||
Net income | $ 4,495 | $ 132,655 |
Other comprehensive income (loss), before tax and net of reclassification adjustments: | ||
Foreign currency translation adjustment | (7,195) | (5,913) |
Unrealized loss on securities available-for-sale | (88) | (2,788) |
Unrealized gain (loss) on derivative instruments | 11,981 | (575) |
Other comprehensive income (loss), before tax | 4,698 | (9,276) |
Tax expense related to items of other comprehensive income | 2,760 | 73 |
Other comprehensive income (loss), net of tax | 1,938 | (9,349) |
Comprehensive income | $ 6,433 | $ 123,306 |
Consolidated Statements of Stockholders' Equity (Parenthetical) - $ / shares |
3 Months Ended | |
---|---|---|
Mar. 31, 2021 |
Mar. 31, 2020 |
|
Statement of Stockholders' Equity [Abstract] | ||
Dividends declared per share (in usd per share) | $ 0.27 | $ 0.26 |
Basis of presentation |
3 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Mar. 31, 2021 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Organization, Consolidation and Presentation of Financial Statements [Abstract] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Basis of presentation | Basis of presentation The accompanying unaudited consolidated financial statements should be read in conjunction with the consolidated financial statements and notes thereto for the year ended December 31, 2020, included in our annual report on Form 10-K (the "2020 Form 10-K") filed with the Securities and Exchange Commission (the "SEC"). In our opinion, the accompanying consolidated financial statements reflect all adjustments (consisting only of normal recurring items) considered necessary to present fairly our financial position at March 31, 2021 and December 31, 2020, the results of our operations and comprehensive income for the three months ended March 31, 2021 and 2020, the cash flows for the three months ended March 31, 2021 and 2020, and the statement of stockholders' equity for the three months ended March 31, 2021 and 2020. Our operating results for the three months ended March 31, 2021 are not necessarily indicative of the results that may be expected for the year ending December 31, 2021. These financial statements have been prepared in accordance with accounting principles generally accepted in the United States ("GAAP"). Reclassifications As further discussed below, certain prior period amounts have been reclassified to conform to the current period presentation. The reclassifications had no impact on our previously reported net income or cash flows: •Before the second quarter of 2020, we included net sales attributable to our operations in India within the EMEIA region in Note 2 - Revenue of Notes to Consolidated Financial Statements. In the second quarter of 2020, we began including these amounts within the APAC (Australia, India, New Zealand, Southeast Asia, China, South Korea and Japan) geographic region, to reflect recent changes within our organizational structure. We have recast historical comparative information to conform to the March 31, 2021 presentation. Refer to Note 2 - Revenue of Notes to Consolidated Financial Statements for our revenue disaggregated by geographic region which now include the Americas (United States, Canada and Latin America), EMEA (Europe, Middle East, and Africa) and APAC. •Before the second quarter of 2020, we presented “Interest income, ” "Net foreign exchange gain (loss), " and "Other income (loss)" separately on the consolidated statements of income. In the second quarter of 2020, we began presenting these amounts within “Other (expense) income” in the consolidated statements of income for all periods presented. Refer to "Other (expense) income" in Note 1 - Basis of Presentation of Notes to Consolidated Financial Statements for additional information on the amounts that comprise "Other (expense) income". Recently Adopted Accounting Pronouncements Clarification of Equity Method Transition In January 2020, the Financial Accounting Standards Board ("FASB") issued Accounting Standards Update ("ASU") 2020-01, “Investments-Equity Securities (Topic 321), Investments-Equity Method and Joint Ventures (Topic 323), and Derivatives and Hedging (Topic 815): Clarifying the Interactions between Topic 321, Topic 323, and Topic 815,” which clarifies the interaction of the accounting for equity investments under Topic 321 and investments accounted for under the equity method of accounting in Topic 323 and the accounting for certain forward contracts and purchased options accounted for under Topic 815. The standard is effective for public companies for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2020. We adopted ASU 2020-01 on January 1, 2021, and the new standard did not have a material impact on our consolidated financial statements and related disclosures. Recently Issued Accounting Pronouncements Reference Rate Reform In March 2020, the FASB issued ASU No. 2020-04, "Reference Rate Reform (Topic 848)," which provides optional expedients for contracts, hedging relationships, and other transactions that reference London Interbank Offered Rate ("LIBOR") or another rate expected to be discontinued at the end of 2021 due to reference rate reform. The update is effective immediately and may be applied prospectively to contracts and other transactions entered into or evaluated on or before December 31, 2022. We are currently evaluating the impact on our consolidated financial position, results of operations, and cash flows. Summary of Significant Accounting Policies There were no significant changes in our accounting policies during the three months ended March 31, 2021 compared to the significant accounting policies described in our 2020 Form 10-K. Divestitures AWR On January 15, 2020, we completed the sale of our AWR Corporation subsidiary ("AWR") for approximately $161 million, subject to final working capital adjustments. We recognized a gain of approximately $160 million on the sale. The gain is included within "Gain on sale of business/assets" in the consolidated statements of income, which also included approximately $1 million of transaction costs. The divestiture of AWR resulted in the derecognition of the following assets and liabilities (in thousands):
Other (Expense) Income Other (expense) income, net consisted of the following amounts (in thousands):
Other Current Liabilities Other current liabilities on our consolidated balance sheet includes the following amounts (in thousands):
Earnings Per Share Basic earnings per share (“EPS”) is computed by dividing net income by the weighted average number of common shares outstanding during each period. Diluted EPS is computed by dividing net income by the weighted average number of common shares and common share equivalents outstanding (if dilutive) during each period. The number of common share equivalents, which includes restricted stock units ("RSUs"), is computed using the treasury stock method. The reconciliation of the denominators used to calculate basic EPS and diluted EPS for the three months ended March 31, 2021 and 2020, are as follows:
Shares issuable upon vesting of RSU awards for the three months ended March 31, 2021 and 2020 of 567,000 shares and 182,000 shares, respectively, were excluded in the computations of diluted EPS because the effect of including the RSU awards would have been anti-dilutive.
|
Revenue |
3 Months Ended | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Mar. 31, 2021 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Revenue from Contract with Customer [Abstract] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Revenue | Revenue Revenue Recognition Revenue is recognized upon transfer of control of the promised products or services to customers in an amount that reflects the consideration we expect to receive in exchange for those products or services. We enter into contracts that can include various combinations of our products or services, which are generally capable of being distinct and accounted for as separate performance obligations. Revenue is recognized net of allowances for returns and any taxes collected from customers, which are subsequently remitted to governmental authorities. Disaggregation of Revenues We disaggregate revenue from contracts with customers based on the timing of transfer of goods or services to customers (point-in-time or over time) and geographic region based on the billing location of the customer. Before the second quarter of 2020, we included net sales attributable to our operations in India within the EMEIA region. In the second quarter of 2020, we began including these amounts within the APAC geographic region, to reflect recent changes within our organizational structure. We have recast historical comparative information to conform to the March 31, 2021 presentation. The geographic regions are now presented as the Americas, EMEA and APAC to reflect this change. Total net sales based on the disaggregation criteria described above are as follows:
Information about Contract Balances Amounts collected in advance of services being provided are accounted for as deferred revenue. Nearly all of our deferred revenue balance is related to extended hardware and software maintenance contracts. Payment terms and conditions vary by contract type, although payment is typically due within 30 to 90 days of contract inception. In instances where the timing of revenue recognition differs from the timing of invoicing, we have determined our contracts generally do not include a significant financing component. The primary purpose of our invoicing terms is to provide customers with simplified and predictable ways of purchasing our products and services, not to receive financing from our customers, such as invoicing at the beginning of a subscription term with a portion of the revenue recognized ratably over the contract period, or to provide customers with financing, such as multi-year on-premises licenses that are invoiced annually with revenue recognized upfront. Changes in deferred revenue, current and non-current, during the three months ended March 31, 2021 were as follows:
For the three months ended March 31, 2021, revenue recognized from performance obligations satisfied in prior periods (for example, due to changes in transaction price) was not material. Amounts recognized as revenue in excess of amounts billed are recorded as unbilled receivables. Unbilled receivables which are anticipated to be invoiced in the next twelve months are included in "other current assets" on the consolidated balance sheet. Based on the nature of our contracts with customers, we do not typically recognize unbilled receivables related to revenues recognized in excess of amounts billed. For the three months ended March 31, 2021 and December 31, 2020, amounts recognized related to unbilled receivables were not material. Unsatisfied Performance Obligations Revenue expected to be recognized in any future period related to remaining performance obligations, excluding revenue pertaining to contracts that have an original expected duration of one year or less, and contracts where revenue is recognized as invoiced, was approximately $61.7 million as of March 31, 2021. Because we typically invoice customers at contract inception, this amount is included in our current and non-current deferred revenue balances. As of March 31, 2021, we expect to recognize approximately 38% of the revenue related to these unsatisfied performance obligations during the remainder of 2021, 35% during 2022, and 27% thereafter. Assets Recognized from the Costs to Obtain a Contract with a Customer We recognize an asset for the incremental costs of obtaining a contract with a customer if we expect the benefit of those costs to be longer than one year. We have determined that certain sales incentive programs meet the requirements to be capitalized. Capitalized incremental costs related to initial contracts and renewals are amortized over the same period because the commissions paid on both the initial contract and renewals are commensurate with one another. Total capitalized costs to obtain a contract were not material during the periods presented and are included in other long-term assets on our consolidated balance sheets.
|
Investments |
3 Months Ended | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Mar. 31, 2021 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Cash, Cash Equivalents, and Short-term Investments [Abstract] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Investments | Investments The following tables summarize unrealized gains and losses related to our short-term investments designated as available-for-sale debt securities:
The following tables summarize the contractual maturities of our short-term investments designated as available-for-sale debt securities:
Equity-Method Investments The carrying value of our equity method investments was $34 million and $25 million as of March 31, 2021 and December 31, 2020, respectively. During the three months ended March 31, 2021, we determined there was an other than temporary impairment for one of our equity-method investments, based on revised forecasts. We recorded a $3.5 million impairment loss related to this investment during the three months ended March 31, 2021. Our proportionate share of the income/(loss) from equity-method investments and related impairment charges are included within "Other (expense) income". Refer to Note 1 - Basis of Presentation of Notes to Consolidated Financial Statements for additional information on these amounts for the three months ended March 31, 2021 and 2020.
|
Fair value measurements |
3 Months Ended | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Mar. 31, 2021 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Fair Value Disclosures [Abstract] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Fair value measurements | Fair value measurements We define fair value to be the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. When determining the fair value measurements for assets and liabilities required or permitted to be recorded at fair value, we consider the principal or most advantageous market that market participants may use when pricing the asset or liability. We follow a fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value. Fair value measurement is determined based on the lowest level input that is significant to the fair value measurement. The three values of the fair value hierarchy are the following: Level 1 – Quoted prices in active markets for identical assets or liabilities Level 2 – Inputs other than quoted prices included within Level 1 that are observable for the asset or liability, either directly or indirectly Level 3 – Inputs that are not based on observable market data Assets and liabilities measured at fair value on a recurring basis are summarized below:
We value our available-for-sale short-term investments based on pricing from third party pricing vendors, who may use quoted prices in active markets for identical assets (Level 1 inputs) or inputs other than quoted prices that are observable either directly or indirectly (Level 2 inputs) in determining fair value. We classify all of our fixed income available-for-sale securities as having Level 2 inputs. The valuation techniques used to measure the fair value of our financial instruments having Level 2 inputs were derived from non-binding market consensus prices that are corroborated by observable market data, quoted market prices for similar instruments, or pricing models, such as discounted cash flow techniques. We believe all of these sources reflect the credit risk associated with each of our available-for-sale short-term investments. Short-term investments available-for-sale consists of debt securities issued by states of the U.S. and political subdivisions of the U.S., corporate debt securities and debt securities issued by U.S. government organizations and agencies. All of our short-term investments available-for-sale have contractual maturities of less than 60 months. Our derivatives consist of foreign currency forward contracts. Our foreign currency forward contracts are valued using an income approach (Level 2) based on the spot rate less the contract rate multiplied by the notional amount. We consider counterparty credit risk in the valuation of our derivatives. However, counterparty credit risk did not impact the valuation of our derivatives during the three months ended March 31, 2021. There were no transfers in or out of Level 1 or Level 2 during the three months ended March 31, 2021. As of March 31, 2021, our short-term investments did not include any foreign sovereign debt. All of our short-term investments that are located outside of the U.S. are denominated in the U.S. dollar. We did not have any items that were measured at fair value on a nonrecurring basis at March 31, 2021 and December 31, 2020. The carrying value of net accounts receivable, accounts payable, and long-term debt contained in the consolidated balance sheets approximates fair value.
|
Derivative instruments and hedging activities |
3 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Mar. 31, 2021 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Derivative Instruments and Hedging Activities Disclosure [Abstract] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Derivative instruments and hedging activities | Derivative instruments and hedging activities We recognize all of our derivative instruments as either assets or liabilities in our statement of financial position at fair value. The accounting for changes in the fair value (i.e., gains or losses) of a derivative instrument depends on whether it has been designated and qualifies as part of a hedging relationship and further, on the type of hedging relationship. For those derivative instruments that are designated and qualify as hedging instruments, we designate the hedging instrument, based upon the exposure being hedged, as a fair value hedge, cash flow hedge, or a hedge of a net investment in a foreign operation. We have direct operations in approximately 40 countries. Sales outside of the Americas accounted for approximately 62% and 60% of our net sales during the three months ended March 31, 2021 and 2020, respectively. Our activities expose us to a variety of market risks, including the effects of changes in foreign currency exchange rates. These financial risks are monitored and managed by us as an integral part of our overall risk management program. We maintain a foreign currency risk management strategy that uses derivative instruments (foreign currency forward contracts) to help protect our earnings and cash flows from fluctuations caused by the volatility in currency exchange rates. Movements in foreign currency exchange rates pose a risk to our operations and competitive position, in that exchange rate changes may affect our profitability and cash flow, and the business or pricing strategies of our non-U.S. based competitors. The vast majority of our foreign sales are denominated in the customers’ local currency. We purchase foreign currency forward contracts as hedges of forecasted sales that are denominated in foreign currencies and as hedges of foreign currency denominated financial assets or liabilities. These contracts are entered into to help protect against the risk that the eventual dollar-net-cash inflows resulting from such sales or firm commitments will be adversely affected by changes in exchange rates. We also purchase foreign currency forward contracts as hedges of forecasted expenses that are denominated in foreign currencies. These contracts are entered into to help protect against the risk that the eventual dollar-net-cash outflows resulting from foreign currency operating and cost of sales expenses will be adversely affected by changes in exchange rates. We designate foreign currency forward contracts as cash flow hedges of forecasted net sales or forecasted expenses. In addition, we hedge our foreign currency denominated balance sheet exposures using foreign currency forward contracts that are not designated as hedging instruments. None of our derivative instruments contain a credit-risk-related contingent feature. Cash flow hedges To help protect against the reduction in value caused by a fluctuation in foreign currency exchange rates of forecasted foreign currency cash flows resulting from international sales over the next to three years, we have instituted a foreign currency cash flow hedging program. We hedge portions of our forecasted net sales and forecasted expenses denominated in foreign currencies with forward contracts. For forward contracts, when the dollar strengthens significantly against the foreign currencies, the change in the present value of future foreign currency cash flows may be offset by the change in the fair value of the forward contracts designated as hedges. We purchase foreign currency forward contracts for up to 100% of our forecasted exposures in selected currencies (primarily in Euro, Japanese yen, Hungarian forint, British pound, Malaysian ringgit, Chinese yuan, and Korean won) and limit the duration of these contracts to 40 months or less. For derivative instruments that are designated and qualify as a cash flow hedge, the gain or loss on the derivative is reported as a component of accumulated other comprehensive income ("OCI") and reclassified into earnings in the same line item (net sales, operating expenses, or cost of sales) associated with the forecasted transaction and in the same period or periods during which the hedged transaction affects earnings. Hedge effectiveness of foreign currency forwards designated as cash flow hedges are measured by comparing the hedging instrument’s cumulative change in fair value from inception to maturity to the forecasted transaction’s terminal value. We held forward contracts designated as cash flow hedges with the following notional amounts:
The contracts in the foregoing table had contractual maturities of 33 months or less and 36 months or less at March 31, 2021 and December 31, 2020, respectively. At March 31, 2021, we expect to reclassify $1.2 million of losses on derivative instruments from accumulated OCI to net sales during the next twelve months when the hedged international sales occur, $0.8 million of losses on derivative instruments from accumulated OCI to cost of sales during the next twelve months when the cost of sales are incurred and $0.6 million of losses on derivative instruments from accumulated OCI to operating expenses during the next twelve months when the hedged operating expenses occur. Expected amounts are based on derivative valuations at March 31, 2021. Actual results may vary materially as a result of changes in the corresponding exchange rates subsequent to this date. Other Derivatives Other derivatives not designated as hedging instruments consist primarily of foreign currency forward contracts that we use to hedge our foreign denominated net receivable or net payable positions to help protect against the change in value caused by a fluctuation in foreign currency exchange rates. We typically attempt to hedge up to 90% of our outstanding foreign denominated net receivables or net payables and typically limit the duration of these foreign currency forward contracts to approximately 90 days or less. The gain or loss on the derivatives as well as the offsetting gain or loss on the hedge item attributable to the hedged risk is recognized in current earnings under the line item “Other (expense) income.” As of March 31, 2021 and December 31, 2020, we held foreign currency forward contracts that were not designated as hedging instruments with a notional amount of $89 million and $89 million, respectively. The following tables present the fair value of derivative instruments on our Consolidated Balance Sheets at March 31, 2021 and December 31, 2020, respectively.
The following tables present the effect of derivative instruments on our Consolidated Statements of Income for the three-months ended March 31, 2021 and 2020, respectively:
|
Inventories, net |
3 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Mar. 31, 2021 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Inventory Disclosure [Abstract] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Inventories, net | Inventories, net Inventories, net consist of the following:
|
Intangible assets and goodwill, net |
3 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Mar. 31, 2021 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Goodwill and Intangible Assets Disclosure [Abstract] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Intangible assets and goodwill, net | Intangible assets and goodwill, net Intangible assets at March 31, 2021 and December 31, 2020 are as follows:
Software development costs capitalized for the three months ended March 31, 2021 and 2020 were $0.3 million and $2.0 million, respectively, and related amortization expenses for the three months ended March 31, 2021 and 2020 were $7.0 million and $7.3 million, respectively. Capitalized software development costs for each of the three months ended March 31, 2021 and 2020 included costs related to stock-based compensation of $0.1 million and $0.1 million, respectively. Amortization of capitalized software development costs is computed on an individual product basis for those products available for market and is recognized based on the product’s estimated economic life, generally to six years. Acquired technology and other intangible assets are amortized over their useful lives, which range from to ten years. Patents are amortized using the straight-line method over their estimated period of benefit, generally to seventeen years. Total intangible assets amortization expenses were $14.0 million and $9.4 million for the three months ended March 31, 2021 and 2020, respectively. Goodwill The carrying amount of goodwill as of March 31, 2021, was as follows:
The excess purchase price over the fair value of assets acquired is recorded as goodwill. As businesses are acquired, we assign assets acquired (including goodwill) and liabilities assumed to either our existing reporting unit or a newly identified reporting unit as of the date of the acquisition. In the event a disposal group meets the definition of a business, goodwill is allocated to the disposal group based on the relative fair value of the disposal group to the related reporting unit. As we have one operating segment comprised of components with similar economic characteristics, we allocate goodwill to one reporting unit for goodwill impairment testing. Goodwill is tested for impairment on an annual basis, and between annual tests if indicators of potential impairment exist, using a fair-value-based approach based on the market capitalization of the reporting unit. Our annual impairment test is performed in the fourth quarter of each year. No impairment of goodwill was identified during the three months ended March 31, 2021 or the twelve months ended December 31, 2020.
|
Leases |
3 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Mar. 31, 2021 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Leases [Abstract] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Leases | Leases We have operating leases for corporate offices, automobiles, and certain equipment. Our leases have remaining terms of 1 year to 93 years, some of which may include options to extend the leases for up to 9 years, and some of which may include options to terminate the lease within 1 year. Leases with an initial term of 12 months or less are not recorded on the balance sheet; we recognize lease expense for these leases on a straight-line basis over the lease term. Amounts related to finance lease activities and income from leasing activities were not material for the periods presented. The components of operating lease expense were as follows (unaudited):
Maturities of lease liabilities as of March 31, 2021 were as follows (unaudited):
As of March 31, 2021, we have additional operating leases that have not commenced during the period, which were not material.
|
Income taxes |
3 Months Ended |
---|---|
Mar. 31, 2021 | |
Income Tax Disclosure [Abstract] | |
Income taxes | Income taxes We account for income taxes under the asset and liability method. Deferred tax assets and liabilities are recognized for the expected tax consequences of temporary differences between the tax bases of assets and liabilities and their reported amounts. Valuation allowances are established when necessary to reduce deferred tax assets to amounts which are more likely than not to be realized. We had a valuation allowance of $94 million and $93 million at March 31, 2021 and December 31, 2020, respectively. A majority of the valuation allowance is related to the deferred tax assets of National Instruments Hungary Kft. (“NI Hungary”). We account for uncertainty in income taxes recognized in our financial statements using prescribed recognition thresholds and measurement attributes for financial statement disclosure of tax positions taken or expected to be taken on our tax returns. We had $10.5 million of gross unrecognized tax benefits at both March 31, 2021 and December 31, 2020, all of which would affect our effective income tax rate if recognized. We recorded a gross increase in unrecognized tax benefits of $29,000 for the three months ended March 31, 2021, as a result of the tax positions taken during this period. As of March 31, 2021, it is reasonably possible that we will recognize gross tax benefits in the amount of $1.4 million in the next twelve months due to the closing of open tax years. The nature of the uncertainty is related to positions taken on returns that have not been examined by the applicable tax authority. Our continuing policy is to recognize interest and penalties related to income tax matters in income tax expense. During the three months ended March 31, 2021, we recognized interest expense related to uncertain tax positions of approximately $36,000. As of March 31, 2021, we had approximately $0.4 million accrued for interest related to uncertain tax positions. The tax years 2014 through 2021 remain open to examination by the major taxing jurisdictions to which we are subject. Our provision for income taxes reflected an effective tax rate of (1)% and 23% for the three months ended March 31, 2021 and 2020, respectively. For the three months ended March 31, 2021, our effective tax rate was lower than the U.S. federal statutory rate of 21% primarily as a result of excess tax benefits from share-based compensation and other discrete items, an enhanced deduction for certain research and development expenses, the research and development tax credit, and the deduction for foreign-derived intangible income, offset by the U.S. tax on global intangible low-taxed income, state income taxes net of federal benefit and nondeductible officer compensation. For the three months ended March 31, 2020, our effective tax rate was higher than the U.S. federal statutory rate of 21% primarily as a result of the gain on the sale of our AWR business, foreign taxes greater than the statutory rate, nondeductible officer compensation, and state income taxes net of the federal benefit, offset by the research and development tax credit, the deduction for foreign-derived intangible income, and an enhanced deduction for certain research and development expenses. Our earnings from our operations in Hungary are subject to a statutory tax rate of 9%. In addition, our research and development activities in Hungary benefit from a tax law in Hungary that provides for an enhanced deduction for qualified research and development expenses. The tax position of our Hungarian operations resulted in income tax benefits of $0.2 million for each of the three months ended March 31, 2021 and March 31, 2020. Earnings from our operations in Malaysia are free of tax under a tax holiday effective January 1, 2013. This tax holiday expires in 2037. If we fail to satisfy the conditions of the tax holiday, this tax benefit may be terminated early. The income tax benefits of the tax holiday for the three months ended March 31, 2021 and March 31, 2020 were approximately $0.1 million and $0.2 million, respectively. The impact of the tax holiday on a per share basis for each of the three months ended March 31, 2021 and March 31, 2020 was a benefit of $0.01 per share. No other taxing jurisdictions had a significant impact on our effective tax rate. We have not entered into any advanced pricing or other agreements with the Internal Revenue Service ("IRS") with regard to any foreign jurisdictions.
|
Comprehensive Income |
3 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Mar. 31, 2021 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Accumulated Other Comprehensive Income (Loss), Net of Tax [Abstract] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Comprehensive income | Comprehensive income Our comprehensive income is comprised of net income, foreign currency translation, unrealized gains and losses on forward contracts and securities classified as available-for-sale. The accumulated OCI, net of tax, for the three months ended March 31, 2021 and 2020, consisted of the following:
|
Authorized shares of common and preferred stock and stock-based compensation plans |
3 Months Ended | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Mar. 31, 2021 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Share-based Payment Arrangement [Abstract] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Authorized shares of common and preferred stock and stock-based compensation plans | Authorized shares of common and preferred stock and stock-based compensation plans Authorized shares of common and preferred stock The total number of shares which we are authorized to issue is 365,000,000 shares, consisting of (i) 5,000,000 shares of preferred stock, par value $0.01 per share, and (ii) 360,000,000 shares of common stock, par value $0.01 per share. Stock-Based Compensation Plan Our stockholders approved our 2005 Incentive Plan (the “2005 Plan”) on May 10, 2005. At the time of approval, 4,050,000 shares of our common stock were reserved for issuance under the 2005 Plan, as well as the number of shares which had been reserved but not issued under our 1994 Incentive Stock Option Plan (the “1994 Plan”), which terminated in May 2005, and any shares that returned to the 1994 Plan as a result of termination of options or repurchase of shares issued under such plan. The 2005 Plan provided for the granting of incentive awards in the form of restricted stock and RSUs to directors, executive officers and employees of the Company and its subsidiaries. Awards vest over a , or ten-year period, beginning on the date of grant. Vesting of ten-year awards may accelerate based on our previous year’s earnings and growth but ten-year awards cannot accelerate to vest over a period of less than five years. The 2005 Plan terminated on May 11, 2010, except with respect to outstanding awards previously granted thereunder. There were 3,362,304 shares of common stock that were reserved but not issued under the 2005 Plan as of May 11, 2010. Our stockholders approved our 2010 Incentive Plan (the “2010 Plan”) on May 11, 2010. At the time of approval, 3,000,000 shares of our common stock were reserved for issuance under the 2010 Plan, as well as the 3,362,304 shares of common stock that were reserved but not issued under the 1994 Plan and the 2005 Plan as of May 11, 2010, and any shares that are returned to the 1994 Plan and the 2005 Plan as a result of the forfeiture or termination of options or RSUs or repurchase of shares issued under those plans. The 2010 Plan provided for the granting of incentive awards in the form of restricted stock and RSUs to employees, directors and consultants of the Company and employees and consultants of any parent or subsidiary of the Company. Awards vest over a , or ten-year period, beginning on the date of grant. Vesting of ten-year awards may accelerate based on our previous year’s earnings and growth but ten-year awards cannot accelerate to vest over a period of less than five years. The 2010 Plan terminated on May 12, 2015, except with respect to the outstanding awards previously granted thereunder. There were 2,518,416 shares of common stock that were reserved but not issued under the 2010 Plan as of May 12, 2015. Our stockholders approved our 2015 Equity Incentive Plan (the “2015 Plan”) on May 12, 2015. At the time of approval, 3,000,000 shares of our common stock were reserved for issuance under the 2015 Plan, as well as the 2,518,416 shares of common stock that were reserved but not issued under the 2010 Plan as of May 12, 2015, and any shares that were returned to the 1994 Plan, 2005 Plan, and 2010 Plan as a result of the forfeiture or termination of options or RSUs or repurchase of shares issued under those plans. The 2015 Plan provides for the granting of incentive awards in the form of restricted stock and RSUs, to employees, directors and consultants of the Company and employees and consultants of any parent or subsidiary of the Company and such awards may be subject to performance-based vesting conditions. Awards generally vest over a , , or ten-year period, beginning on the date of grant. Vesting of ten-year awards may accelerate based on our previous year’s earnings and growth but ten year awards cannot accelerate to vest over a period of less than five years. The 2015 Plan terminated on May 5, 2020, except with respect to the outstanding awards previously granted thereunder. There were 567,142 shares of common stock that were reserved but not issued under the 2015 Plan as of May 5, 2020. Our stockholders approved our 2020 Equity Incentive Plan (the “2020 Plan”) on May 5, 2020. At the time of approval, 4,500,000 shares of our common stock were reserved for issuance under the 2020 Plan, as well as the 567,142 shares of common stock that were reserved but not issued under the 2015 Plan as of May 5, 2020, and any shares that were returned to the 1994 Plan, 2005 Plan, 2010 Plan, and 2015 Plan as a result of the forfeiture or termination of options or RSUs or repurchase of shares issued under those plans. The 2020 Plan provides for the granting of incentive awards in the form of restricted stock and RSUs to employees, directors and consultants of the Company and employees and consultants of any parent or subsidiary of the Company. Awards generally vest over a , , or four-year period, beginning on the date of the grant and awards may be subject to performance-based vesting conditions. There were 3,307,988 shares available for grant under the 2020 Plan at March 31, 2021. Performance-based stock units During the three months ended March 31, 2021 and 2020, we granted 130,006 and 144,647 performance-based restricted stock units ("PRSUs"), respectively, to executive officers pursuant to the 2020 Plan and 2015 Plan. The PRSUs may be earned based on our total shareholder return ("TSR") compared to the TSR of the Russell 2000 Index (the “Index”) over a three-year performance period. For the PRSUs granted during the three months ended March 31, 2021, the three-year performance period commenced on January 1, 2021, and will end on December 31, 2023, and for the PRSUs granted during the three months ended March 31, 2020, the three-year performance commenced on January 1, 2020 and will end on December 31, 2022, using the average daily closing price over a 30-day lookback in each case. The number of awards earned could range from zero to two times the target number of shares granted. The fair values of PRSUs are estimated using a Monte Carlo simulation. The determination of fair values of the PRSUs are based on our stock price and a number of assumptions including the expected volatility, expected dividend yield and the risk-free interest rate. The expected volatility at the date of grant was based on the historical volatilities of our stock and the companies included in the Index over the performance period. The Monte Carlo model is based on random projections of stock-price paths and must be repeated numerous times to achieve a probabilistic assessment. The key assumptions used in valuing these market-based awards are as follows:
The weighted average grant date fair value of the market-based awards, as determined by the Monte Carlo valuation model, was $66.97 per share and $61.00 per share in 2021 and 2020, respectively. Employee stock purchase plan Our employee stock purchase plan ("ESPP") permits substantially all domestic employees and employees of designated subsidiaries to acquire our common stock at a purchase price of 85% of the lower of the market price at the beginning or the end of the purchase period. The plan has quarterly purchase periods generally beginning on February 1, May 1, August 1 and November 1 of each year. Employees may designate up to 15% of their compensation for the purchase of common stock under the ESPP. On May 14, 2019, our stockholders approved an additional 3,000,000 shares for issuance under the ESPP. At March 31, 2021, we had 2,737,080 shares of common stock reserved for future issuance under the ESPP. We issued 322,112 shares under this plan in the three months ended March 31, 2021 and the weighted average purchase price of the shares issued was $26.59 per share. During the three months ended March 31, 2021, we did not make any changes in accounting principles or methods of estimates with respect to our ESPP. Authorized Preferred Stock and Preferred Stock Purchase Rights Plan We have 5,000,000 authorized shares of preferred stock. On January 21, 2004, our Board of Directors designated 750,000 of these shares as Series A Participating Preferred Stock in conjunction with the adoption of a Preferred Stock Rights Agreement which expired on May 10, 2014. There were no shares of preferred stock issued and outstanding at March 31, 2021. Stock repurchases and retirements On April 21, 2010, our Board of Directors authorized a program to repurchase shares of our common stock from time to time, depending on market conditions and other factors. The Board amended such program several times over the years to increase the number of shares that may be purchased under the program. Most recently, on October 23, 2019, our Board amended the program to increase the number of shares that may be repurchased by 3,000,000 shares. At March 31, 2021, there were 1,609,943 shares remaining available for repurchase under the stock repurchase program. We did not repurchase any shares of our common stock during the three-months ended March 31, 2021 under the program. We repurchased 164,873 shares of our common stock at a weighted average price per share of $39.58 during the three-months ended March 31, 2020 under the program.
|
Segment and geographic information |
3 Months Ended | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Mar. 31, 2021 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Segment Reporting [Abstract] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Segment and Geographic Information | Segment and geographic information We operate as one operating segment. Operating segments are defined as components of an enterprise for which separate financial information is evaluated regularly by the chief operating decision maker, who is our chief executive officer, in deciding how to allocate resources and in assessing performance. Our chief operating decision maker evaluates our financial information and resources and assesses the performance of these resources on a consolidated basis. Since we operate as one operating segment, all required financial segment information can be found in the condensed consolidated financial statements and the notes thereto. We sell our products in three geographic regions which consist of Americas, EMEA and APAC. Our sales to these regions share similar economic characteristics, similar product mix, similar customers, and similar distribution methods. Revenue from the sale of our products, which are similar in nature, and software maintenance is reflected as total net sales in our Consolidated Statements of Income. (See Note 2 –Revenue of Notes to Consolidated Financial Statements for total net sales by the major geographic areas in which we operate). The following tables present summarized information for net sales by country. Revenues from external customers are generally attributed to countries based upon the customer's location. Net sales attributable to each individual foreign country outside the U.S. and China were not material.
Total property and equipment, net, outside the U.S. was $131 million and $135 million as of March 31, 2021 and December 31, 2020, respectively. Revenues and long-lived assets attributable to each individual foreign country outside of the U.S. were not material.
|
Debt |
3 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Mar. 31, 2021 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt Disclosure [Abstract] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt | DebtOn October 30, 2020, we entered into a First Amendment to our Amended and Restated Credit Agreement (the" Amendment"), which amended the prior agreement, dated as of June 12, 2020 with Wells Fargo Bank, National Association, as Administrative Agent, and Lenders party thereto (as amended, the "Credit Agreement"). The Credit Agreement provides for a $115 million revolving line of credit and a $100 million term loan. Subject to the terms of the Credit Agreement, we may borrow additional funds of up to $100 million, plus an unlimited amount so long as after giving effect to the incurrence of such incremental increases, on a pro forma basis, the consolidated total leverage ratio does not exceed 2.25 to 1.00. The maturity date of both the revolving line of credit and term loan is June 12, 2024 (the "Maturity Date"). The term loan shall be paid after the effective date for the Amendment in quarterly installments equal to 1.25% of the original principal amount and shall be paid in full, with accrued interest, on the Maturity Date. The revolving loans and term loans accrue interest, at our option, at: (i) a basis rate equal to the highest of (a) the prime rate (b) the federal funds rate plus 0.50%, and (c) LIBOR for an interest period of one month plus 1.00%, plus a margin of 0.50% to 1.00%; or (ii) LIBOR plus margin of 1.50% to 2.00%, in each case with the margin being determined based upon our consolidated total leverage ratio. The Credit Agreement provides for a revolving credit commitment fee of 0.250% to 0.375% per annum, determined based upon our consolidated total leverage ratio, on the average daily unused amount of the revolving committed amount, payable quarterly in arrears. The Credit Agreement contains financial covenants requiring us to maintain a maximum total leverage ratio of less than or equal to 2.75 to 1.00 and a minimum fixed charge coverage ratio of greater than or equal to 1.25 to 1.00, in each case determined in accordance with the Credit Agreement. The Credit Agreement requires that certain of our wholly-owned domestic subsidiaries guaranty our obligations under the Credit Agreement. Obligations under the Credit Agreement and guaranty are secured by substantially all of our and of each guarantying subsidiary's assets. The Credit Agreement also contains customary affirmative and negative covenants. Proceeds of loans made under the revolving loan facility portion of the Credit Agreement may be used for working capital and other general corporate purposes. We may prepay the loans under the Credit Agreement in whole or in part at any time without premium or penalty. The following table presents the amounts outstanding related to our borrowing arrangements discussed above as of March 31, 2021, and December 31, 2020, respectively (in thousands):
|
Commitments and contingencies |
3 Months Ended | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Mar. 31, 2021 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Commitments and Contingencies Disclosure [Abstract] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Commitments and contingencies | Commitments and contingencies We offer a one-year limited warranty on most hardware products which is included in the terms of sale of such products. We also offer optional extended warranties on our hardware products for which the related revenue is recognized ratably over the warranty period. Provision is made for estimated future warranty costs at the time of the sale for the estimated costs that may be incurred under the standard warranty. Our estimate is based on historical experience and product sales during the period. The warranty reserve for the three months ended March 31, 2021 and 2020 was as follows:
|
Restructuring |
3 Months Ended | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Mar. 31, 2021 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Restructuring and Related Activities [Abstract] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Restructuring | Restructuring On October 29, 2020, we announced a workforce reduction plan (the “Plan”) intended to accelerate our growth strategy and further optimize our operations and cost structure. The majority of charges related to this plan were recognized during the three months ended December 31, 2020. The Plan is expected to result in additional reductions to our worldwide headcount of approximately 3% over the next three to six months. In connection with the Plan, we currently estimate that we will incur additional pre-tax charges of approximately $3 million, consisting primarily of cash termination benefits and other employee-related costs that will be paid over the next three to six months. A summary of the charges in the consolidated statement of operations resulting from our restructuring activities is shown below:
A summary of balance sheet activity related to the restructuring activity is shown below:
The restructuring liability of $14.0 million at March 31, 2021 relating primarily to severance payments associated with the restructuring activity, is recorded in the “accrued compensation” line item of the consolidated balance sheet.
|
Litigation |
3 Months Ended |
---|---|
Mar. 31, 2021 | |
Litigation Settlement [Abstract] | |
Litigation | Litigation We are not currently a party to any material litigation. However, in the ordinary course of our business, we have in the past, are currently and will likely become involved in various legal proceedings, claims, and regulatory, tax or government inquiries and investigations, and could incur uninsured liability in any one or more of them. We also periodically receive notifications from various third parties related to alleged infringement of patents or intellectual property rights, commercial disputes or other matters. No assurances can be given with respect to the extent or outcome of any investigation, litigation or dispute. |
Acquisitions |
3 Months Ended | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Mar. 31, 2021 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Business Combinations [Abstract] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Acquisitions | Acquisitions Acquisition of OptimalPlus On July 2, 2020, we completed the acquisition of OptimalPlus Ltd. (“OptimalPlus”), a global leader in data analytics software for the semiconductor, automotive and electronics industries that is based in Israel. As a result of acquiring 100% of the outstanding share capital of OptimalPlus, OptimalPlus became our wholly-owned subsidiary. This transaction is being accounted for as a business combination using the acquisition method of accounting. All of the acquired assets and liabilities of OptimalPlus have been recorded at their respective fair values as of the acquisition date. Transaction costs have been expensed as incurred. The acquisition was funded primarily by cash on hand in addition to $70 million drawn under our term loan facility on June 30, 2020. See Note 13 – Debt of Notes to Consolidated Financial Statements for further information on our outstanding borrowings. During the twelve months ended December 31, 2020, we expensed $7 million of transaction costs in connection with the acquisition of OptimalPlus, which are included in selling, general and administrative expenses. At the acquisition date, total consideration transferred was approximately $353 million, inclusive of $18 million in cash acquired. Additionally, unvested in-the-money share options of certain OptimalPlus employees were exchanged into the right to receive deferred cash consideration in accordance with the terms of the share purchase agreement. Approximately $12 million of deferred cash consideration was allocated to post-combination expense and is not included in the total consideration transferred. The deferred cash consideration is subject to the original vesting schedule of the corresponding unvested options that were replaced and the amounts will be recognized as compensation expense over the remaining service period. The excess of the purchase price over the net assets acquired was recorded as goodwill. Goodwill generated from the acquisition is primarily attributable to expected growth in the scope of and market opportunities for our software-defined automated test and measurement platform. As a result of the structure of the transaction, the balance of goodwill is deductible in the U.S. over 15 years for income tax purposes. Fair value of net assets acquired and liabilities assumed The information below represents the preliminary purchase price allocation of OptimalPlus (in thousands):
Our preliminary estimates of the fair value of the assets acquired and the liabilities assumed are based on the information currently available, and we are continuing to evaluate the underlying inputs and assumptions used in our valuations. Accordingly, these preliminary estimates are subject to change during the measurement period, which is up to one year from the date of acquisition. A decrease in the fair value of assets acquired or an increase in the fair value of liabilities assumed in the acquisition from these preliminary estimates would result in a corresponding increase in the amount of goodwill acquired. The primary areas of the purchase price that are not yet finalized relate to income taxes, indemnification assets, and residual goodwill. Acquired intangible assets will be amortized over their estimated useful lives on a straight-line basis. The following table summarizes the preliminary purchase price allocation, and the preliminary average remaining useful lives, for identifiable intangible assets acquired (dollars in thousands):
Developed technology and IPR&D relate to software platforms for data analytics in the semiconductor, automotive, and electronic industries that combine machine-learning with a global data infrastructure to provide real-time product analytics and extract insights from data across the entire supply chain. We valued the developed technology and IPR&D using the multi-period excess earnings method under the income approach. This method reflects the present value of the projected cash flows that are expected to be generated by the technology less charges representing the contribution of other assets to those cash flows. The economic useful life was determined based on the technology cycle related to each technology, as well as the cash flows over the forecast period. Customer relationships represent the fair value of future projected revenue that will be derived from sales of products to existing customers. Customer relationships were valued using the with-and-without-method under the income approach. In the with-and-without method, the fair value was measured by the difference between the present values of the cash flows with and without the existing customers in place over the period of time necessary to reacquire the customers. The economic useful life was determined by evaluating many factors, including the useful life of other intangible assets, the length of time remaining on the acquired contracts and the historical customer turnover rates. Unaudited Pro Forma Information The results of OptimalPlus have been included in our consolidated statements of income for the period subsequent to the acquisition date. The following unaudited pro forma financial information presents combined results of operations for the periods presented, as if the OptimalPlus acquisition had occurred on January 1, 2019, with adjustments to give effect to pro forma events that are directly attributable to the acquisition. These pro forma adjustments include additional amortization expense for the identifiable intangible assets, a reduction in revenue related to deferred revenue purchase accounting adjustments, an increase in interest expense related to the term loan entered into in connection with the acquisition, and adjustments to compensation expense for the replacement of unvested share options discussed above, net of tax effects. For the pro forma presentation, given the assumed acquisition date of January 1, 2019, transaction and integration costs that were incurred at or subsequent to the actual acquisition date have been included in the calculation of pro forma net income for the three months ended March 31, 2020, whereas transaction and integration costs that were incurred prior to the acquisition date have been excluded from the calculation of pro forma net income. The unaudited pro forma results are presented for informational purposes only and are not necessarily indicative of what actual results of operations would have been if the acquisition had occurred as the beginning of the period presented, nor are they indicative of future results of operations. The unaudited pro forma results do not include the impact of synergies, nor any potential impacts on current or future market conditions which could alter the unaudited pro forma results.
|
Subsequent events |
3 Months Ended |
---|---|
Mar. 31, 2021 | |
Subsequent Events [Abstract] | |
Subsequent events | Subsequent events On April 21, 2021, our Board of Directors declared a quarterly cash dividend of $0.27 per common share, payable on June 1, 2021, to stockholders of record on May 10, 2021. On April 23, 2021, we acquired the outstanding share capital of a software company for cash consideration of approximately $20 million. The transaction is expected to be accounted for as a business combination.
|
Basis of presentation (Policies) |
3 Months Ended |
---|---|
Mar. 31, 2021 | |
Organization, Consolidation and Presentation of Financial Statements [Abstract] | |
Basis of presentation | Basis of presentation The accompanying unaudited consolidated financial statements should be read in conjunction with the consolidated financial statements and notes thereto for the year ended December 31, 2020, included in our annual report on Form 10-K (the "2020 Form 10-K") filed with the Securities and Exchange Commission (the "SEC"). In our opinion, the accompanying consolidated financial statements reflect all adjustments (consisting only of normal recurring items) considered necessary to present fairly our financial position at March 31, 2021 and December 31, 2020, the results of our operations and comprehensive income for the three months ended March 31, 2021 and 2020, the cash flows for the three months ended March 31, 2021 and 2020, and the statement of stockholders' equity for the three months ended March 31, 2021 and 2020. Our operating results for the three months ended March 31, 2021 are not necessarily indicative of the results that may be expected for the year ending December 31, 2021. These financial statements have been prepared in accordance with accounting principles generally accepted in the United States ("GAAP"). Reclassifications As further discussed below, certain prior period amounts have been reclassified to conform to the current period presentation. The reclassifications had no impact on our previously reported net income or cash flows: •Before the second quarter of 2020, we included net sales attributable to our operations in India within the EMEIA region in Note 2 - Revenue of Notes to Consolidated Financial Statements. In the second quarter of 2020, we began including these amounts within the APAC (Australia, India, New Zealand, Southeast Asia, China, South Korea and Japan) geographic region, to reflect recent changes within our organizational structure. We have recast historical comparative information to conform to the March 31, 2021 presentation. Refer to Note 2 - Revenue of Notes to Consolidated Financial Statements for our revenue disaggregated by geographic region which now include the Americas (United States, Canada and Latin America), EMEA (Europe, Middle East, and Africa) and APAC. •Before the second quarter of 2020, we presented “Interest income, ” "Net foreign exchange gain (loss), " and "Other income (loss)" separately on the consolidated statements of income. In the second quarter of 2020, we began presenting these amounts within “Other (expense) income” in the consolidated statements of income for all periods presented. Refer to "Other (expense) income" in Note 1 - Basis of Presentation of Notes to Consolidated Financial Statements for additional information on the amounts that comprise "Other (expense) income". Summary of Significant Accounting Policies There were no significant changes in our accounting policies during the three months ended March 31, 2021 compared to the significant accounting policies described in our 2020 Form 10-K.
|
Recently Adopted Accounting Pronouncements and Recently Issued Accounting Pronouncements | Recently Adopted Accounting Pronouncements Clarification of Equity Method Transition In January 2020, the Financial Accounting Standards Board ("FASB") issued Accounting Standards Update ("ASU") 2020-01, “Investments-Equity Securities (Topic 321), Investments-Equity Method and Joint Ventures (Topic 323), and Derivatives and Hedging (Topic 815): Clarifying the Interactions between Topic 321, Topic 323, and Topic 815,” which clarifies the interaction of the accounting for equity investments under Topic 321 and investments accounted for under the equity method of accounting in Topic 323 and the accounting for certain forward contracts and purchased options accounted for under Topic 815. The standard is effective for public companies for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2020. We adopted ASU 2020-01 on January 1, 2021, and the new standard did not have a material impact on our consolidated financial statements and related disclosures. Recently Issued Accounting Pronouncements Reference Rate Reform In March 2020, the FASB issued ASU No. 2020-04, "Reference Rate Reform (Topic 848)," which provides optional expedients for contracts, hedging relationships, and other transactions that reference London Interbank Offered Rate ("LIBOR") or another rate expected to be discontinued at the end of 2021 due to reference rate reform. The update is effective immediately and may be applied prospectively to contracts and other transactions entered into or evaluated on or before December 31, 2022. We are currently evaluating the impact on our consolidated financial position, results of operations, and cash flows.
|
Earnings Per Share | Earnings Per ShareBasic earnings per share (“EPS”) is computed by dividing net income by the weighted average number of common shares outstanding during each period. Diluted EPS is computed by dividing net income by the weighted average number of common shares and common share equivalents outstanding (if dilutive) during each period. The number of common share equivalents, which includes restricted stock units ("RSUs"), is computed using the treasury stock method. |
Basis of presentation (Tables) |
3 Months Ended | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Mar. 31, 2021 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Organization, Consolidation and Presentation of Financial Statements [Abstract] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Schedule of Derecognition of Assets and Liabilities | The divestiture of AWR resulted in the derecognition of the following assets and liabilities (in thousands):
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Schedule of Other (Expense) Income, net | Other (expense) income, net consisted of the following amounts (in thousands):
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Schedule of Other Current Liabilities | Other current liabilities on our consolidated balance sheet includes the following amounts (in thousands):
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reconciliation of the Denominators used to Calculate Basic and Diluted EPS | The reconciliation of the denominators used to calculate basic EPS and diluted EPS for the three months ended March 31, 2021 and 2020, are as follows:
|
Revenue (Tables) |
3 Months Ended | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Mar. 31, 2021 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Revenue from Contract with Customer [Abstract] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Disaggregation of Revenue | Total net sales based on the disaggregation criteria described above are as follows:
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Changes in Unearned Revenue | Changes in deferred revenue, current and non-current, during the three months ended March 31, 2021 were as follows:
|
Investments (Tables) |
3 Months Ended | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Mar. 31, 2021 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Cash, Cash Equivalents, and Short-term Investments [Abstract] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Schedule of Available-for-sale Securities Reconciliation | The following tables summarize unrealized gains and losses related to our short-term investments designated as available-for-sale debt securities:
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Investments Classified by Contractual Maturity Date | The following tables summarize the contractual maturities of our short-term investments designated as available-for-sale debt securities:
|
Fair value measurements (Tables) |
3 Months Ended | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Mar. 31, 2021 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Fair Value Disclosures [Abstract] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis | Assets and liabilities measured at fair value on a recurring basis are summarized below:
|
Derivative instruments and hedging activities (Tables) |
3 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Mar. 31, 2021 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Derivative Instruments and Hedging Activities Disclosure [Abstract] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Schedule of Forward Contracts Notional Amount | We held forward contracts designated as cash flow hedges with the following notional amounts:
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Schedule of Fair Value of Derivative Instruments | The following tables present the fair value of derivative instruments on our Consolidated Balance Sheets at March 31, 2021 and December 31, 2020, respectively.
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Schedule of Effect of Derivative Instruments | The following tables present the effect of derivative instruments on our Consolidated Statements of Income for the three-months ended March 31, 2021 and 2020, respectively:
|
Inventories, net (Tables) |
3 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Mar. 31, 2021 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Inventory Disclosure [Abstract] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Schedule of Inventory, Net | Inventories, net consist of the following:
|
Intangible assets and goodwill, net (Tables) |
3 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Mar. 31, 2021 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Goodwill and Intangible Assets Disclosure [Abstract] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Schedule of Finite-Lived Intangible Assets | Intangible assets at March 31, 2021 and December 31, 2020 are as follows:
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Schedule of Goodwill | The carrying amount of goodwill as of March 31, 2021, was as follows:
|
Leases (Tables) |
3 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Mar. 31, 2021 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Leases [Abstract] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Components of Lease Expense | The components of operating lease expense were as follows (unaudited):
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Schedule of Future Minimum Lease Payments | Maturities of lease liabilities as of March 31, 2021 were as follows (unaudited):
|
Comprehensive income (Tables) |
3 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Mar. 31, 2021 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Accumulated Other Comprehensive Income (Loss), Net of Tax [Abstract] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Schedule of Comprehensive Income (Loss) | The accumulated OCI, net of tax, for the three months ended March 31, 2021 and 2020, consisted of the following:
|
Authorized shares of common and preferred stock and stock-based compensation plans (Tables) |
3 Months Ended | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Mar. 31, 2021 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Share-based Payment Arrangement [Abstract] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Schedule of Key Assumptions to Value Market-based Awards | The key assumptions used in valuing these market-based awards are as follows:
|
Segment and geographic information (Tables) |
3 Months Ended | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Mar. 31, 2021 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Segment Reporting [Abstract] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Schedule of Net Sales by Country | The following tables present summarized information for net sales by country. Revenues from external customers are generally attributed to countries based upon the customer's location. Net sales attributable to each individual foreign country outside the U.S. and China were not material.
|
Debt (Tables) |
3 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Mar. 31, 2021 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt Disclosure [Abstract] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Schedule of Amounts Outstanding related to Borrowing Arrangements | The following table presents the amounts outstanding related to our borrowing arrangements discussed above as of March 31, 2021, and December 31, 2020, respectively (in thousands):
|
Commitments and contingencies (Tables) |
3 Months Ended | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Mar. 31, 2021 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Commitments and Contingencies Disclosure [Abstract] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Schedule of Product Warranty Liability | The warranty reserve for the three months ended March 31, 2021 and 2020 was as follows:
|
Restructuring (Tables) |
3 Months Ended | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Mar. 31, 2021 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Restructuring and Related Activities [Abstract] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Summary of Charges Resulting From Restructuring Activities | A summary of the charges in the consolidated statement of operations resulting from our restructuring activities is shown below:
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Schedule of Restructuring Reserve by Type of Cost | A summary of balance sheet activity related to the restructuring activity is shown below:
|
Acquisitions (Tables) |
3 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Mar. 31, 2021 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Business Combinations [Abstract] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Schedule of Preliminary Purchase Price Allocation | The information below represents the preliminary purchase price allocation of OptimalPlus (in thousands):
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Summary of Preliminary Purchase Price Allocation and Useful Lives | The following table summarizes the preliminary purchase price allocation, and the preliminary average remaining useful lives, for identifiable intangible assets acquired (dollars in thousands):
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Schedule of Pro Forma Information |
|
Basis of Presentation - Narrative (Details) - USD ($) $ in Thousands |
3 Months Ended | ||
---|---|---|---|
Jan. 15, 2020 |
Mar. 31, 2021 |
Mar. 31, 2020 |
|
New Accounting Pronouncements or Change in Accounting Principle [Line Items] | |||
Gain on sale of business/assets | $ 0 | $ 159,753 | |
Divestiture by sale | AWR Corporation | |||
New Accounting Pronouncements or Change in Accounting Principle [Line Items] | |||
Proceeds from sale of business | $ 161,000 | ||
Gain on sale of business/assets | 160,000 | ||
Transaction costs | $ 1,000 |
Basis of Presentation - Disposal Groups, Including Discontinued Operations (Details) - Divestiture by sale - AWR Corporation $ in Thousands |
Jan. 15, 2020
USD ($)
|
---|---|
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items] | |
Cash | $ 1,027 |
Accounts receivable, net | 7,233 |
Prepaid and other current assets | 283 |
Goodwill | 7,221 |
Other non-current assets | 556 |
Total assets | 16,320 |
Deferred revenue | 15,296 |
Other current liabilities | 940 |
Cumulative translation adjustment | (660) |
Total liabilities and stockholders' equity | 15,576 |
Total assets divested, net (including cash) | $ 744 |
Basis of Presentation - Schedule of Other Income (Expense) (Details) - USD ($) $ in Thousands |
3 Months Ended | |
---|---|---|
Mar. 31, 2021 |
Mar. 31, 2020 |
|
Organization, Consolidation and Presentation of Financial Statements [Abstract] | ||
Interest income | $ 161 | $ 2,299 |
Interest expense | (704) | (76) |
Loss from equity-method investments | (4,173) | (1,025) |
Net foreign exchange loss | (559) | (505) |
Other | 205 | (133) |
Other (expense) income, net | $ (5,070) | $ 560 |
Basis of Presentation - Schedule of Other Current Liabilities (Details) - USD ($) $ in Thousands |
Mar. 31, 2021 |
Dec. 31, 2020 |
---|---|---|
Organization, Consolidation and Presentation of Financial Statements [Abstract] | ||
Income taxes payable - current | $ 14,255 | $ 13,720 |
Hedge payable - current | 8,553 | 13,031 |
Other | 19,413 | 15,827 |
Other current liabilities | $ 42,221 | $ 42,578 |
Basis of Presentation - Schedule of Earnings Per Share (Details) - shares |
3 Months Ended | |
---|---|---|
Mar. 31, 2021 |
Mar. 31, 2020 |
|
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items] | ||
Weighted average shares outstanding - basic (in shares) | 131,483,000 | 130,613,000 |
Plus: Common share equivalents | ||
RSUs (in shares) | 1,234,000 | 744,000 |
Weighted average shares outstanding-diluted (in shares) | 132,717,000 | 131,357,000 |
RSU | ||
Plus: Common share equivalents | ||
Anti-dilutive securities excluded from the computation of diluted EPS (in shares) | 567,000 | 182,000 |
Revenue - Disaggregation of Revenues (Details) - USD ($) $ in Thousands |
3 Months Ended | |
---|---|---|
Mar. 31, 2021 |
Mar. 31, 2020 |
|
Disaggregation of Revenue [Line Items] | ||
Total net sales | $ 335,182 | $ 309,381 |
Americas | ||
Disaggregation of Revenue [Line Items] | ||
Total net sales | 126,733 | 125,017 |
EMEA | ||
Disaggregation of Revenue [Line Items] | ||
Total net sales | 85,522 | 86,729 |
APAC | ||
Disaggregation of Revenue [Line Items] | ||
Total net sales | 122,927 | 97,635 |
Point-in-Time | ||
Disaggregation of Revenue [Line Items] | ||
Total net sales | 281,453 | 260,310 |
Point-in-Time | Americas | ||
Disaggregation of Revenue [Line Items] | ||
Total net sales | 104,586 | 105,299 |
Point-in-Time | EMEA | ||
Disaggregation of Revenue [Line Items] | ||
Total net sales | 64,237 | 67,822 |
Point-in-Time | APAC | ||
Disaggregation of Revenue [Line Items] | ||
Total net sales | 112,630 | 87,189 |
Over Time | ||
Disaggregation of Revenue [Line Items] | ||
Total net sales | 53,729 | 49,071 |
Over Time | Americas | ||
Disaggregation of Revenue [Line Items] | ||
Total net sales | 22,147 | 19,718 |
Over Time | EMEA | ||
Disaggregation of Revenue [Line Items] | ||
Total net sales | 21,285 | 18,907 |
Over Time | APAC | ||
Disaggregation of Revenue [Line Items] | ||
Total net sales | $ 10,297 | $ 10,446 |
Revenue - Changes in Unearned Revenue (Details) $ in Thousands |
3 Months Ended |
---|---|
Mar. 31, 2021
USD ($)
| |
Movement in Deferred Revenue [Roll Forward] | |
Deferred revenue, beginning balance | $ 168,486 |
Deferral of revenue billed in current period, net of recognition | 50,032 |
Recognition of revenue deferred in prior periods | (51,525) |
Foreign currency translation impact | (3,188) |
Deferred revenue, ending balance | $ 163,805 |
Revenue - Narrative (Details) $ in Millions |
3 Months Ended |
---|---|
Mar. 31, 2021
USD ($)
| |
Revenue from Contract with Customer [Abstract] | |
Payment terms | Amounts collected in advance of services being provided are accounted for as deferred revenue. Nearly all of our deferred revenue balance is related to extended hardware and software maintenance contracts. Payment terms and conditions vary by contract type, although payment is typically due within 30 to 90 days of contract inception. |
Undelivered performance obligation | $ 61.7 |
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2021-04-01 | |
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items] | |
Remaining performance obligation, percent | 38.00% |
Performance obligation, term | 9 months |
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2022-01-01 | |
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items] | |
Remaining performance obligation, percent | 35.00% |
Performance obligation, term | 1 year |
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2023-01-01 | |
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items] | |
Remaining performance obligation, percent | 27.00% |
Performance obligation, term |
Investments - Unrealized Gains And Losses Related To Short-Term Investments Designated As Available-For-Sale (Details) - USD ($) $ in Thousands |
Mar. 31, 2021 |
Dec. 31, 2020 |
---|---|---|
Debt Securities, Available-for-sale [Line Items] | ||
Adjusted Cost | $ 32,097 | $ 59,761 |
Gross Unrealized Gain | 74 | 163 |
Gross Unrealized Loss | 0 | (1) |
Fair Value | 32,171 | 59,923 |
Corporate bonds | ||
Debt Securities, Available-for-sale [Line Items] | ||
Adjusted Cost | 32,097 | 59,761 |
Gross Unrealized Gain | 74 | 163 |
Gross Unrealized Loss | 0 | (1) |
Fair Value | $ 32,171 | $ 59,923 |
Investments - Contractual Maturities Of Short-Term Investments Designated As Available-For-Sale (Details) - USD ($) $ in Thousands |
3 Months Ended | |
---|---|---|
Mar. 31, 2021 |
Dec. 31, 2020 |
|
Adjusted Cost | ||
Due in less than 1 year | $ 32,097 | |
Adjusted Cost | 32,097 | $ 59,761 |
Fair Value | ||
Due in less than 1 year | 32,171 | |
Fair Value | 32,171 | 59,923 |
Carrying value of equity method investments | 34,000 | 25,000 |
Impairment loss | 3,500 | |
Corporate bonds | ||
Adjusted Cost | ||
Due in less than 1 year | 32,097 | |
Fair Value | ||
Due in less than 1 year | 32,171 | |
Fair Value | $ 32,171 | $ 59,923 |
Fair value measurements (Details) - USD ($) $ in Thousands |
Mar. 31, 2021 |
Dec. 31, 2020 |
---|---|---|
Short-term investments available for sale | ||
Available-for-sale | $ 32,171 | $ 59,923 |
Derivatives | 7,712 | 6,124 |
Total Assets | 186,443 | 211,513 |
Derivatives | (11,126) | (19,359) |
Total Liabilities | $ (11,126) | (19,359) |
Short-term investments contractual maturity (in months) | 60 months | |
Quoted Prices in Active Markets for Identical Assets (Level 1) | ||
Short-term investments available for sale | ||
Derivatives | $ 0 | 0 |
Total Assets | 146,560 | 145,466 |
Derivatives | 0 | 0 |
Total Liabilities | 0 | 0 |
Significant Other Observable Inputs (Level 2) | ||
Short-term investments available for sale | ||
Derivatives | 7,712 | 6,124 |
Total Assets | 39,883 | 66,047 |
Derivatives | (11,126) | (19,359) |
Total Liabilities | (11,126) | (19,359) |
Significant Unobservable Inputs (Level 3) | ||
Short-term investments available for sale | ||
Derivatives | 0 | |
Total Assets | 0 | 0 |
Derivatives | 0 | 0 |
Total Liabilities | 0 | 0 |
Money Market Funds | ||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ||
Cash and cash equivalents available for sale | 146,560 | 145,466 |
Money Market Funds | Quoted Prices in Active Markets for Identical Assets (Level 1) | ||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ||
Cash and cash equivalents available for sale | 146,560 | 145,466 |
Money Market Funds | Significant Other Observable Inputs (Level 2) | ||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ||
Cash and cash equivalents available for sale | 0 | 0 |
Money Market Funds | Significant Unobservable Inputs (Level 3) | ||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ||
Cash and cash equivalents available for sale | 0 | 0 |
Corporate notes and bonds | ||
Short-term investments available for sale | ||
Available-for-sale | 32,171 | 59,923 |
Corporate notes and bonds | Quoted Prices in Active Markets for Identical Assets (Level 1) | ||
Short-term investments available for sale | ||
Available-for-sale | 0 | 0 |
Corporate notes and bonds | Significant Other Observable Inputs (Level 2) | ||
Short-term investments available for sale | ||
Available-for-sale | 32,171 | 59,923 |
Corporate notes and bonds | Significant Unobservable Inputs (Level 3) | ||
Short-term investments available for sale | ||
Available-for-sale | $ 0 | $ 0 |
Derivative instruments and hedging activities - Narrative (Details) $ in Thousands |
3 Months Ended | 12 Months Ended | |
---|---|---|---|
Mar. 31, 2021
USD ($)
country
|
Mar. 31, 2020 |
Dec. 31, 2020
USD ($)
|
|
Derivative [Line Items] | |||
Number of countries for which entity has direct operations | country | 40 | ||
Percentage of sales outside of the Americas during the period | 60.00% | ||
Period of protection against the reduction in value caused by a fluctuation, minimum (in number of years) | 1 year | ||
Period of protection against the reduction in value caused by a fluctuation, maximum (in number of years) | 3 years | ||
Foreign currency forward contracts notional amount | $ 455,306 | $ 504,179 | |
Net Assets, Geographic Area | Non-Americas | |||
Derivative [Line Items] | |||
Concentration risk, percentage | 62.00% | ||
Forward Contracts | |||
Derivative [Line Items] | |||
Duration of time, foreign currency cash flow hedge | 40 months | ||
Forward Contracts | Net sales | |||
Derivative [Line Items] | |||
Gains (losses) expected to be reclassified from AOCI to earnings | $ (1,200) | ||
Forward Contracts | Operating expenses | |||
Derivative [Line Items] | |||
Gains (losses) expected to be reclassified from AOCI to earnings | (800) | ||
Forward Contracts | Cost of sales | |||
Derivative [Line Items] | |||
Gains (losses) expected to be reclassified from AOCI to earnings | (600) | ||
Other Derivatives | |||
Derivative [Line Items] | |||
Foreign currency forward contracts notional amount | $ 89,000 | $ 89,000 | |
Maximum | |||
Derivative [Line Items] | |||
Duration of foreign currency forward contracts | 33 months | 36 months | |
Maximum | Forward Contracts | |||
Derivative [Line Items] | |||
Percentage of derivative risk hedged | 100.00% | ||
Maximum | Other Derivatives | |||
Derivative [Line Items] | |||
Percentage of derivative risk hedged | 90.00% | ||
Duration of foreign currency forward contracts | 90 days |
Derivative instruments and hedging activities - Summary Of Notional Amounts Of Derivative Instruments (Details) - USD ($) $ in Thousands |
Mar. 31, 2021 |
Dec. 31, 2020 |
---|---|---|
Derivative [Line Items] | ||
Total forward contracts notional amount | $ 455,306 | $ 504,179 |
Chinese yuan | ||
Derivative [Line Items] | ||
Total forward contracts notional amount | 52,702 | 45,553 |
Euro | ||
Derivative [Line Items] | ||
Total forward contracts notional amount | 187,833 | 219,115 |
Japanese yen | ||
Derivative [Line Items] | ||
Total forward contracts notional amount | 61,908 | 73,399 |
Hungarian forint | ||
Derivative [Line Items] | ||
Total forward contracts notional amount | 76,118 | 82,429 |
British pound | ||
Derivative [Line Items] | ||
Total forward contracts notional amount | 26,706 | 25,133 |
Malaysian ringgit | ||
Derivative [Line Items] | ||
Total forward contracts notional amount | 31,294 | 36,249 |
Korean won | ||
Derivative [Line Items] | ||
Total forward contracts notional amount | $ 18,745 | $ 22,301 |
Derivative instruments and hedging activities - Fair Values Of Derivative Instruments On Consolidated Balance Sheets (Details) - USD ($) $ in Thousands |
Mar. 31, 2021 |
Dec. 31, 2020 |
---|---|---|
Derivatives, Fair Value [Line Items] | ||
Derivative assets | $ 7,712 | $ 6,124 |
Derivative liability | (11,126) | (19,359) |
Derivatives designated as hedging instruments | ||
Derivatives, Fair Value [Line Items] | ||
Derivative assets | 6,944 | 4,681 |
Derivative liability | (9,161) | (18,877) |
Derivatives designated as hedging instruments | Foreign exchange contracts - ST forwards | Prepaid expenses and other current assets | ||
Derivatives, Fair Value [Line Items] | ||
Derivative assets | 3,885 | 1,564 |
Derivatives designated as hedging instruments | Foreign exchange contracts - ST forwards | Other current liabilities | ||
Derivatives, Fair Value [Line Items] | ||
Derivative liability | (6,588) | (12,549) |
Derivatives designated as hedging instruments | Foreign exchange contracts - LT forwards | Other long-term assets | ||
Derivatives, Fair Value [Line Items] | ||
Derivative assets | 3,059 | 3,117 |
Derivatives designated as hedging instruments | Foreign exchange contracts - LT forwards | Other long-term liabilities | ||
Derivatives, Fair Value [Line Items] | ||
Derivative liability | (2,573) | (6,328) |
Derivatives not designated as hedging instruments | ||
Derivatives, Fair Value [Line Items] | ||
Derivative assets | 768 | 1,443 |
Derivative liability | (1,965) | (482) |
Derivatives not designated as hedging instruments | Foreign exchange contracts - ST forwards | Prepaid expenses and other current assets | ||
Derivatives, Fair Value [Line Items] | ||
Derivative assets | 768 | 1,443 |
Derivatives not designated as hedging instruments | Foreign exchange contracts - ST forwards | Other current liabilities | ||
Derivatives, Fair Value [Line Items] | ||
Derivative liability | $ (1,965) | $ (482) |
Derivative instruments and hedging activities - Effect Of Derivative Instruments On Consolidated Statements Of Income (Details) - USD ($) $ in Thousands |
3 Months Ended | |
---|---|---|
Mar. 31, 2021 |
Mar. 31, 2020 |
|
Derivatives designated as hedging instruments | ||
Derivative Instruments, Gain (Loss) [Line Items] | ||
Gain or (Loss) Recognized in OCI on Derivative | $ 11,981 | $ (575) |
Gain or (Loss) Reclassified from Accumulated OCI into Income | (2,056) | 1,570 |
Derivatives designated as hedging instruments | Foreign exchange contracts - forwards | Net sales | ||
Derivative Instruments, Gain (Loss) [Line Items] | ||
Gain or (Loss) Reclassified from Accumulated OCI into Income | 2,534 | |
Derivatives designated as hedging instruments | Foreign exchange contracts - forwards | Cost of sales | ||
Derivative Instruments, Gain (Loss) [Line Items] | ||
Gain or (Loss) Reclassified from Accumulated OCI into Income | (519) | |
Derivatives designated as hedging instruments | Foreign exchange contracts - forwards | Operating expenses | ||
Derivative Instruments, Gain (Loss) [Line Items] | ||
Gain or (Loss) Reclassified from Accumulated OCI into Income | (445) | |
Derivatives designated as hedging instruments | Foreign exchange contracts 1 | ||
Derivative Instruments, Gain (Loss) [Line Items] | ||
Gain or (Loss) Recognized in OCI on Derivative | 16,286 | 10,856 |
Derivatives designated as hedging instruments | Foreign exchange contracts 1 | Net sales | ||
Derivative Instruments, Gain (Loss) [Line Items] | ||
Gain or (Loss) Reclassified from Accumulated OCI into Income | (2,026) | |
Derivatives designated as hedging instruments | Foreign exchange contracts 2 | ||
Derivative Instruments, Gain (Loss) [Line Items] | ||
Gain or (Loss) Recognized in OCI on Derivative | (2,529) | (6,760) |
Derivatives designated as hedging instruments | Foreign exchange contracts 2 | Cost of sales | ||
Derivative Instruments, Gain (Loss) [Line Items] | ||
Gain or (Loss) Reclassified from Accumulated OCI into Income | (21) | |
Derivatives designated as hedging instruments | Foreign exchange contracts 3 | ||
Derivative Instruments, Gain (Loss) [Line Items] | ||
Gain or (Loss) Recognized in OCI on Derivative | (1,776) | (4,671) |
Derivatives designated as hedging instruments | Foreign exchange contracts 3 | Operating expenses | ||
Derivative Instruments, Gain (Loss) [Line Items] | ||
Gain or (Loss) Reclassified from Accumulated OCI into Income | (9) | |
Derivatives not designated as hedging instruments | ||
Derivative Instruments, Gain (Loss) [Line Items] | ||
Amount of Gain (Loss) Recognized in Income | (1,601) | 297 |
Derivatives not designated as hedging instruments | Foreign exchange contracts - forwards | ||
Derivative Instruments, Gain (Loss) [Line Items] | ||
Amount of Gain (Loss) Recognized in Income | $ (1,601) | $ 297 |
Inventories, net (Details) - USD ($) $ in Thousands |
Mar. 31, 2021 |
Dec. 31, 2020 |
---|---|---|
Inventory Disclosure [Abstract] | ||
Raw materials | $ 103,128 | $ 99,942 |
Work-in-process | 10,014 | 11,307 |
Finished goods | 84,037 | 82,763 |
Total | $ 197,179 | $ 194,012 |
Intangible assets and goodwill, net - Schedule Of Finite-Lived Intangible Assets (Details) - USD ($) $ in Thousands |
Mar. 31, 2021 |
Dec. 31, 2020 |
---|---|---|
Finite-Lived Intangible Assets [Line Items] | ||
Gross Carrying Amount | $ 323,343 | $ 324,253 |
Accumulated Amortization | (163,704) | (151,534) |
Net Carrying Amount | 159,639 | 172,719 |
Capitalized software development costs | ||
Finite-Lived Intangible Assets [Line Items] | ||
Gross Carrying Amount | 115,570 | 115,251 |
Accumulated Amortization | (90,690) | (83,706) |
Net Carrying Amount | 24,880 | 31,545 |
Acquired technology | ||
Finite-Lived Intangible Assets [Line Items] | ||
Gross Carrying Amount | 105,008 | 105,486 |
Accumulated Amortization | (21,391) | (17,913) |
Net Carrying Amount | 83,617 | 87,573 |
Customer relationships | ||
Finite-Lived Intangible Assets [Line Items] | ||
Gross Carrying Amount | 39,866 | 40,273 |
Accumulated Amortization | (11,622) | (10,026) |
Net Carrying Amount | 28,244 | 30,247 |
Patents | ||
Finite-Lived Intangible Assets [Line Items] | ||
Gross Carrying Amount | 36,002 | 35,803 |
Accumulated Amortization | (26,018) | (25,578) |
Net Carrying Amount | 9,984 | 10,225 |
Other | ||
Finite-Lived Intangible Assets [Line Items] | ||
Gross Carrying Amount | 26,897 | 27,440 |
Accumulated Amortization | (13,983) | (14,311) |
Net Carrying Amount | $ 12,914 | $ 13,129 |
Intangible assets and goodwill, net - Narrative (Details) |
3 Months Ended | 12 Months Ended | |
---|---|---|---|
Mar. 31, 2021
USD ($)
segment
|
Mar. 31, 2020
USD ($)
|
Dec. 31, 2020
USD ($)
|
|
Finite-Lived Intangible Assets [Line Items] | |||
Amortization of intangible assets | $ 14,000,000.0 | $ 9,400,000 | |
Number of operating segments | segment | 1 | ||
Goodwill impairment | $ 0 | $ 0 | |
Capitalized software development costs | |||
Finite-Lived Intangible Assets [Line Items] | |||
Software development costs capitalized | 300,000 | 2,000,000.0 | |
Amortization expense of capitalized software development costs | 7,000,000.0 | 7,300,000 | |
Costs related to stock based compensation | $ 100,000 | $ 100,000 | |
Capitalized software development costs | Minimum | |||
Finite-Lived Intangible Assets [Line Items] | |||
Intangible assets amortization period (in years) | 3 years | ||
Capitalized software development costs | Maximum | |||
Finite-Lived Intangible Assets [Line Items] | |||
Intangible assets amortization period (in years) | 6 years | ||
Acquired technology | Minimum | |||
Finite-Lived Intangible Assets [Line Items] | |||
Intangible assets amortization period (in years) | 5 years | ||
Acquired technology | Maximum | |||
Finite-Lived Intangible Assets [Line Items] | |||
Intangible assets amortization period (in years) | 10 years | ||
Patents | Minimum | |||
Finite-Lived Intangible Assets [Line Items] | |||
Intangible assets amortization period (in years) | 3 years | ||
Patents | Maximum | |||
Finite-Lived Intangible Assets [Line Items] | |||
Intangible assets amortization period (in years) | 17 years |
Intangible assets and goodwill, net - Schedule of Goodwill (Details) $ in Thousands |
3 Months Ended |
---|---|
Mar. 31, 2021
USD ($)
| |
Goodwill [Roll Forward] | |
Balance at beginning of period | $ 467,547 |
Measurement period adjustment | (327) |
Foreign currency translation impact | (4,574) |
Balance at end of period | $ 462,646 |
Leases - Summary of Components of Lease Expense and Other Information (Details) - USD ($) $ in Thousands |
3 Months Ended | |
---|---|---|
Mar. 31, 2021 |
Mar. 31, 2020 |
|
Lessee, Lease, Description [Line Items] | ||
Operating lease, termination period | 1 year | |
Operating lease cost | $ 5,330 | $ 5,682 |
Minimum | ||
Lessee, Lease, Description [Line Items] | ||
Operating lease, remaining lease term | 1 year | |
Maximum | ||
Lessee, Lease, Description [Line Items] | ||
Operating lease, remaining lease term | 93 years | |
Operating lease, option to extend, term | 9 years |
Leases - Maturities of Operating Lease Liabilities (Details) $ in Thousands |
Mar. 31, 2021
USD ($)
|
---|---|
Leases [Abstract] | |
2021 (Excluding the three months ended March 31, 2021) | $ 12,763 |
2022 | 11,448 |
2023 | 7,852 |
2024 | 6,929 |
2025 | 4,912 |
Thereafter | 7,017 |
Total future minimum lease payments | 50,921 |
Less imputed interest | (4,526) |
Total | $ 46,395 |
Income taxes (Details) - USD ($) $ / shares in Units, $ in Thousands |
3 Months Ended | ||
---|---|---|---|
Mar. 31, 2021 |
Mar. 31, 2020 |
Dec. 31, 2020 |
|
Operating Loss Carryforwards [Line Items] | |||
Valuation allowance | $ 94,000 | $ 93,000 | |
Unrecognized tax benefits | 10,500 | $ 10,500 | |
Gross increase in unrecognized tax benefits, current period | 29 | ||
Reasonable possibility of future tax benefits | 1,400 | ||
Interest expense related to uncertain tax positions | 36 | ||
Accrued interest related to uncertain tax positions | $ 400 | ||
Effective income tax rate | (1.00%) | 23.00% | |
Hungary statutory tax rate | 9.00% | ||
Hungary | |||
Operating Loss Carryforwards [Line Items] | |||
Foreign income tax benefit | $ 200 | $ 200 | |
Malaysia | |||
Operating Loss Carryforwards [Line Items] | |||
Income tax benefit of tax holiday, amount | $ 100 | $ 200 | |
Income tax benefit of tax holiday (in usd per share) | $ 0.01 | $ 0.01 |
Comprehensive income (Details) - USD ($) $ in Thousands |
3 Months Ended | |
---|---|---|
Mar. 31, 2021 |
Mar. 31, 2020 |
|
AOCI Attributable to Parent, Net of Tax [Roll Forward] | ||
Beginning balance | $ 1,224,871 | $ 1,176,350 |
Current-period other comprehensive (loss) income | 2,642 | (7,706) |
Reclassified from accumulated OCI into income | 2,056 | (1,570) |
Income tax (benefit) expense | 2,760 | 73 |
Ending Balance | 1,221,509 | 1,280,117 |
Currency translation adjustment | ||
AOCI Attributable to Parent, Net of Tax [Roll Forward] | ||
Beginning balance | (10,066) | (25,831) |
Current-period other comprehensive (loss) income | (7,195) | (5,913) |
Reclassified from accumulated OCI into income | 0 | 0 |
Income tax (benefit) expense | 0 | 0 |
Ending Balance | (17,261) | (31,744) |
Investments | ||
AOCI Attributable to Parent, Net of Tax [Roll Forward] | ||
Beginning balance | (426) | (85) |
Current-period other comprehensive (loss) income | (88) | (2,788) |
Reclassified from accumulated OCI into income | 0 | 0 |
Income tax (benefit) expense | (2) | (108) |
Ending Balance | (512) | (2,765) |
Derivative instruments | ||
AOCI Attributable to Parent, Net of Tax [Roll Forward] | ||
Beginning balance | (10,334) | 4,846 |
Current-period other comprehensive (loss) income | 9,925 | 995 |
Reclassified from accumulated OCI into income | 2,056 | (1,570) |
Income tax (benefit) expense | 2,762 | 181 |
Ending Balance | (1,115) | 4,090 |
Accumulated other comprehensive income/(loss) | ||
AOCI Attributable to Parent, Net of Tax [Roll Forward] | ||
Beginning balance | (20,826) | (21,070) |
Ending Balance | $ (18,888) | $ (30,419) |
Authorized shares of common and preferred stock and stock-based compensation plans - Narrative (Details) - $ / shares |
3 Months Ended | |||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|
Jan. 01, 2020 |
May 12, 2015 |
Mar. 31, 2021 |
Mar. 31, 2020 |
Dec. 31, 2020 |
May 05, 2020 |
Oct. 23, 2019 |
May 14, 2019 |
May 14, 2013 |
May 11, 2010 |
May 31, 2005 |
Jan. 21, 2004 |
|
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ||||||||||||
Common and preferred stock shares authorized (in shares) | 365,000,000 | |||||||||||
Preferred stock, authorized (in shares) | 5,000,000 | 5,000,000 | 5,000,000 | |||||||||
Preferred stock, par value per share (in usd per share) | $ 0.01 | $ 0.01 | $ 0.01 | |||||||||
Common stock, authorized (in shares) | 360,000,000 | 360,000,000 | 3,000,000 | 360,000,000 | ||||||||
Common stock, par value per share (in usd per share) | $ 0.01 | $ 0.01 | $ 0.01 | |||||||||
Maximum employee subscription rate | 15.00% | |||||||||||
Preferred stock, issued (in shares) | 0 | 0 | ||||||||||
Preferred stock, outstanding (in shares) | 0 | 0 | ||||||||||
Authorized common stock available for repurchase (in shares) | 1,609,943 | 3,000,000 | ||||||||||
Common stock repurchased (in shares) | 164,873 | |||||||||||
Shares repurchased, weighted average price (in dollars per share) | $ 39.58 | |||||||||||
Series A Preferred Stock | ||||||||||||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ||||||||||||
Preferred stock, authorized (in shares) | 750,000 | |||||||||||
Performance Shares | ||||||||||||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ||||||||||||
Number of shares granted (in shares) | 130,006 | 144,647 | ||||||||||
Service period | 3 years | 3 years | ||||||||||
Weighted average grant day fair value (in dollars per share) | $ 66.97 | $ 61.00 | ||||||||||
Minimum | ||||||||||||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ||||||||||||
Percentage of target shares granted | 0.00% | |||||||||||
Maximum | ||||||||||||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ||||||||||||
Percentage of target shares granted | 200.00% | |||||||||||
Incentive Plan 2005 | ||||||||||||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ||||||||||||
Number of shares reserved for issuance (in shares) | 3,362,304 | 4,050,000 | ||||||||||
Award vesting period (in years) | 10 years | |||||||||||
Incentive Plan 2005 | Vesting period one | ||||||||||||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ||||||||||||
Award vesting period (in years) | 3 years | |||||||||||
Incentive Plan 2005 | Vesting period two | ||||||||||||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ||||||||||||
Award vesting period (in years) | 5 years | |||||||||||
Incentive Plan 2005 | Vesting period three | ||||||||||||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ||||||||||||
Award vesting period (in years) | 10 years | |||||||||||
Incentive Plan 2005 | Minimum | ||||||||||||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ||||||||||||
Award vesting period (in years) | 5 years | |||||||||||
Incentive Plan 2010 | ||||||||||||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ||||||||||||
Common stock, authorized (in shares) | 3,000,000 | |||||||||||
Number of shares reserved for issuance (in shares) | 2,518,416 | |||||||||||
Incentive Plan 2010 | Vesting period one | ||||||||||||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ||||||||||||
Award vesting period (in years) | 3 years | |||||||||||
Incentive Plan 2010 | Vesting period two | ||||||||||||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ||||||||||||
Award vesting period (in years) | 5 years | |||||||||||
Incentive Plan 2010 | Vesting period three | ||||||||||||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ||||||||||||
Award vesting period (in years) | 10 years | |||||||||||
Incentive Plans 1994 and 2005 | ||||||||||||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ||||||||||||
Number of shares reserved for issuance (in shares) | 3,362,304 | |||||||||||
Incentive Plan 2015 | ||||||||||||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ||||||||||||
Additional number of shares reserved for issuance (in shares) | 3,000,000 | |||||||||||
Shares available for grant under 2015 restricted stock plan (in shares) | 567,142 | |||||||||||
Incentive Plan 2015 | Vesting period one | ||||||||||||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ||||||||||||
Award vesting period (in years) | 3 years | |||||||||||
Incentive Plan 2015 | Vesting period two | ||||||||||||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ||||||||||||
Award vesting period (in years) | 4 years | |||||||||||
Incentive Plan 2015 | Vesting period three | ||||||||||||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ||||||||||||
Award vesting period (in years) | 5 years | |||||||||||
Incentive Plan 2015 | Vesting period four | ||||||||||||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ||||||||||||
Award vesting period (in years) | 10 years | |||||||||||
Incentive Plan 2020 | ||||||||||||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ||||||||||||
Number of shares reserved for issuance (in shares) | 4,500,000 | |||||||||||
Shares available for grant under 2015 restricted stock plan (in shares) | 3,307,988 | |||||||||||
Incentive Plan 2020 | Vesting period one | ||||||||||||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ||||||||||||
Award vesting period (in years) | 1 year | |||||||||||
Incentive Plan 2020 | Vesting period two | ||||||||||||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ||||||||||||
Award vesting period (in years) | 2 years | |||||||||||
Incentive Plan 2020 | Vesting period three | ||||||||||||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ||||||||||||
Award vesting period (in years) | 3 years | |||||||||||
Incentive Plan 2020 | Vesting period four | ||||||||||||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ||||||||||||
Award vesting period (in years) | 4 years | |||||||||||
Employee Stock Purchase Plan | ||||||||||||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ||||||||||||
Percentage of the lower of the market related to purchase of common stock | 85.00% | |||||||||||
Common stock reserved for future issuance under employee stock purchase plan (in shares) | 2,737,080 | |||||||||||
Shares issued under employee stock purchase plan (in shares) | 322,112 | |||||||||||
Weighted average purchase price of employees' purchase rights (in usd per share) | $ 26.59 |
Authorized shares of common and preferred stock and stock-based compensation plans (Details) - Performance Shares - simulation simulation in Thousands |
3 Months Ended | |
---|---|---|
Mar. 31, 2021 |
Mar. 31, 2020 |
|
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ||
Number of simulations | 100 | 100 |
Expected volatility | 40.60% | 27.41% |
Expected life in years | 2 years 11 months 12 days | 2 years 11 months 1 day |
Risk-free interest rate | 0.21% | 1.38% |
Dividend yield | 2.66% | 2.32% |
Segment and geographic information- Narrative (Details) $ in Thousands |
3 Months Ended | |
---|---|---|
Mar. 31, 2021
USD ($)
segment
region
|
Dec. 31, 2020
USD ($)
|
|
Revenues from External Customers and Long-Lived Assets [Line Items] | ||
Number of operating segments | segment | 1 | |
Number of geographic regions company operates in | region | 3 | |
Property, plant and equipment, net | $ 252,320 | $ 254,399 |
Outside U.S. | ||
Revenues from External Customers and Long-Lived Assets [Line Items] | ||
Property, plant and equipment, net | $ 131,000 | $ 135,000 |
Segment and geographic information - Schedule of Revenue by Geographic Region (Details) - USD ($) $ in Thousands |
3 Months Ended | |
---|---|---|
Mar. 31, 2021 |
Mar. 31, 2020 |
|
Segment Reporting Information [Line Items] | ||
Total net sales | $ 335,182 | $ 309,381 |
United States | ||
Segment Reporting Information [Line Items] | ||
Total net sales | 120,000 | 118,000 |
China | ||
Segment Reporting Information [Line Items] | ||
Total net sales | 54,000 | 34,000 |
Rest of the World | ||
Segment Reporting Information [Line Items] | ||
Total net sales | $ 161,000 | $ 157,000 |
Debt - Narrative (Details) |
Oct. 30, 2020
USD ($)
|
---|---|
Minimum | |
Line of Credit Facility [Line Items] | |
Quarterly fee | 125.00% |
Secured Revolving Loan Facility | Line of Credit | |
Line of Credit Facility [Line Items] | |
Unsecured revolving line of credit | $ 115,000,000 |
Term Loan | Secured Revolving Loan Facility | Line of Credit | |
Line of Credit Facility [Line Items] | |
Unsecured revolving line of credit | 100,000,000 |
Secured Term Loan Facility | Revolving Credit Facility | |
Line of Credit Facility [Line Items] | |
Additional funds available | $ 100,000,000 |
Credit Agreement | |
Line of Credit Facility [Line Items] | |
Total leverage ratio | 2.75 |
Credit Agreement | Revolving Credit Facility | |
Line of Credit Facility [Line Items] | |
Total leverage ratio | 2.25 |
Quarterly installments, percent of principal | 1.25% |
Credit Agreement | Revolving Credit Facility | Federal funds rate | |
Line of Credit Facility [Line Items] | |
Variable interest rate spread | 0.50% |
Credit Agreement | Revolving Credit Facility | One month LIBOR | |
Line of Credit Facility [Line Items] | |
Variable interest rate spread | 1.00% |
Credit Agreement | Revolving Credit Facility | Minimum | |
Line of Credit Facility [Line Items] | |
Quarterly commitment fee | 0.25% |
Credit Agreement | Revolving Credit Facility | Minimum | Margin | |
Line of Credit Facility [Line Items] | |
Variable interest rate spread | 0.50% |
Credit Agreement | Revolving Credit Facility | Minimum | LIBOR | |
Line of Credit Facility [Line Items] | |
Variable interest rate spread | 1.50% |
Credit Agreement | Revolving Credit Facility | Maximum | |
Line of Credit Facility [Line Items] | |
Quarterly commitment fee | 0.375% |
Credit Agreement | Revolving Credit Facility | Maximum | Margin | |
Line of Credit Facility [Line Items] | |
Variable interest rate spread | 1.00% |
Credit Agreement | Revolving Credit Facility | Maximum | LIBOR | |
Line of Credit Facility [Line Items] | |
Variable interest rate spread | 2.00% |
Debt - Schedule of Long-term Debt Instruments (Details) - USD ($) $ in Thousands |
Mar. 31, 2021 |
Dec. 31, 2020 |
Mar. 31, 2020 |
---|---|---|---|
Line of Credit Facility [Line Items] | |||
Total Debt | $ 97,500 | $ 98,750 | |
Less: Unamortized debt issuance costs | (1,509) | (1,714) | |
Less: Current Portion of Total Debt | (5,000) | (5,000) | |
Total Debt, non-current | $ 90,991 | 92,036 | |
Term Loan | |||
Line of Credit Facility [Line Items] | |||
Effective interest rate | 1.70% | 1.70% | |
Total Debt | $ 97,500 | $ 98,750 |
Commitments and contingencies - Narrative (Details) $ in Millions |
3 Months Ended |
---|---|
Mar. 31, 2021
USD ($)
| |
Commitments and Contingencies Disclosure [Abstract] | |
Limited warranty on most hardware products (in number of years) | 1 year |
Non-cancelable purchase commitments | $ 4.6 |
Commitments and contingencies - Schedule Of Warranty Reserve (Details) - USD ($) $ in Thousands |
3 Months Ended | |
---|---|---|
Mar. 31, 2021 |
Mar. 31, 2020 |
|
Movement in Standard Product Warranty Accrual [Roll Forward] | ||
Balance at the beginning of the period | $ 2,872 | $ 2,561 |
Accruals for warranties issued during the period | 681 | 597 |
Accruals related to pre-existing warranties | 130 | 63 |
Settlements made (in cash or in kind) during the period | (803) | (599) |
Balance at the end of the period | $ 2,880 | $ 2,622 |
Restructuring - Narrative (Details) - USD ($) $ in Thousands |
6 Months Ended | ||
---|---|---|---|
Sep. 30, 2021 |
Mar. 31, 2021 |
Dec. 31, 2020 |
|
Restructuring Cost and Reserve [Line Items] | |||
Restructuring, expected cost | $ 3,000 | ||
Restructuring liability | $ 14,026 | $ 28,993 | |
Forecast | |||
Restructuring Cost and Reserve [Line Items] | |||
Expected percentage of headcount reduction | 3.00% |
Restructuring - Summary of Charges in Consolidated Statement of Operations (Details) - USD ($) $ in Thousands |
3 Months Ended | |
---|---|---|
Mar. 31, 2021 |
Mar. 31, 2020 |
|
Restructuring Cost and Reserve [Line Items] | ||
Total restructuring and other related costs | $ 6,275 | $ 11,250 |
Cost of sales | ||
Restructuring Cost and Reserve [Line Items] | ||
Total restructuring and other related costs | 75 | 20 |
Research and development | ||
Restructuring Cost and Reserve [Line Items] | ||
Total restructuring and other related costs | 155 | 4,600 |
Sales and marketing | ||
Restructuring Cost and Reserve [Line Items] | ||
Total restructuring and other related costs | 4,086 | 6,315 |
General and administrative | ||
Restructuring Cost and Reserve [Line Items] | ||
Total restructuring and other related costs | $ 1,959 | $ 315 |
Restructuring - Summary of Balance Sheet Activity (Details) - USD ($) $ in Thousands |
3 Months Ended | |
---|---|---|
Mar. 31, 2021 |
Mar. 31, 2020 |
|
Restructuring Reserve [Roll Forward] | ||
Restructuring reserve | $ 28,993 | |
Income statement expense | 6,275 | $ 11,250 |
Cash payments | (21,242) | |
Restructuring reserve | $ 14,026 |
Acquisitions - Narrative (Details) - USD ($) $ in Thousands |
Jul. 02, 2020 |
Jun. 30, 2020 |
Dec. 31, 2020 |
---|---|---|---|
Term loan facility | Wells Fargo Securities, LLC | Line of Credit | |||
Business Acquisition [Line Items] | |||
Proceeds from term loan | $ 70,000 | ||
Optimal Plus Ltd | |||
Business Acquisition [Line Items] | |||
Percentage of voting interests acquired | 100.00% | ||
Transaction costs | $ 7,000 | ||
Consideration Transferred | $ 352,642 | ||
Cash acquired from acquisition | 18,000 | ||
Deferred cash consideration | $ 12,000 |
Acquisitions - Schedule of Preliminary Purchase Price Allocation (Details) - USD ($) $ in Thousands |
Jul. 02, 2020 |
Mar. 31, 2021 |
Dec. 31, 2020 |
---|---|---|---|
Business Acquisition [Line Items] | |||
Intangible assets | $ 129,000 | ||
Goodwill | $ 462,646 | $ 467,547 | |
Optimal Plus Ltd | |||
Business Acquisition [Line Items] | |||
Consideration Transferred | 352,642 | ||
Cash | 17,661 | ||
Goodwill | 202,738 | ||
Contract assets | 15,454 | ||
Deferred revenue | (7,341) | ||
Accounts receivable | 4,927 | ||
Other assets and liabilities | (2,216) | ||
Deferred tax liabilities | (7,581) | ||
Net assets acquired | $ 352,642 |
Acquisitions - Summary of Preliminary Purchase Price Allocation and Useful Lives (Details) - Optimal Plus Ltd - USD ($) $ in Thousands |
3 Months Ended | |
---|---|---|
Jul. 02, 2020 |
Mar. 31, 2021 |
|
Business Acquisition [Line Items] | ||
Estimated Fair Value | $ 129,000 | |
In-process research and development (IPR&D) | ||
Business Acquisition [Line Items] | ||
Estimated Fair Value | 10,400 | |
Customer relationships | ||
Business Acquisition [Line Items] | ||
Estimated Fair Value | $ 30,100 | |
Estimated Useful Lives (in years) | 5 years | |
Acquired technology | ||
Business Acquisition [Line Items] | ||
Estimated Fair Value | $ 82,400 | |
Estimated Useful Lives (in years) | 6 years | |
Other intangibles | ||
Business Acquisition [Line Items] | ||
Estimated Fair Value | $ 6,100 | |
Other intangibles | Minimum | ||
Business Acquisition [Line Items] | ||
Estimated Useful Lives (in years) | 3 years | |
Other intangibles | Maximum | ||
Business Acquisition [Line Items] | ||
Estimated Useful Lives (in years) | 5 years |
Acquisitions - Pro Forma Information (Details) - Optimal Plus Ltd $ in Thousands |
3 Months Ended |
---|---|
Mar. 31, 2020
USD ($)
| |
Business Acquisition [Line Items] | |
Net sales | $ 315,170 |
Net income | $ 120,991 |
Subsequent events (Details) - USD ($) $ / shares in Units, $ in Millions |
3 Months Ended | |||
---|---|---|---|---|
Apr. 23, 2021 |
Apr. 21, 2021 |
Mar. 31, 2021 |
Mar. 31, 2020 |
|
Subsequent Event [Line Items] | ||||
Dividends declared per share (in usd per share) | $ 0.27 | $ 0.26 | ||
Subsequent event | ||||
Subsequent Event [Line Items] | ||||
Dividends declared per share (in usd per share) | $ 0.27 | |||
cash payment | $ 20 |
F!\HCEB'_P%02P,$%
M @ S'.C4GD/J<(R!P %!X !@ !X;"]W;W)K =450DZJQ 6)GG;2XVQ$F>7[=?L*^/P21,ICF!%<40IN$T
MS2$-QUD*CWB2P)62[=-4$8*1!Y@?OBO2)/WQV*9AG(_[?[^[**,P6*+ %3=#
MP#U=+/J+X2 =DOIDG+I__"0>3Q)G@S$)TW'B?,^3U+5)F"2Y[Q5A8?WYRBS^
M_^0[F;J!581+WAF[!0,?A[XAA>%G0ET?&\FG;7OM //KU]F_^06
M#XO9,LTWLOA'Y.9P/4MF*.<[=BK,%_GX*V\6%-GY,EEH]Q<]-K;!#&4G;639
M# 8%I:CJ7_;4..)L ,SC'T": :0_(!P90)L!U"VT5N:6]8$9MEXI^8B4M8;9
M[(7SC1L-JQ&5W<9[H^"_ L:9]4966A8B9X;GZ-[ #^R1T>C/'=HP?4"?8)\U
MFJ.O]Q_0SS_]@GY"HD)_'>1)LRK7JX4!#7:F1=:\[[9^'QEY'T6?964.&GVL
MB:K3!0<5:UB
M^]S>9=951R4?!$0"VCZ_V5EQJRF>=-8'H8]2LP+MH:PAJ!UPS9'
J.3^_A.HU.@UKO4Z'W]5X&MIC\5D%(GQ<#SZBKQ)
M8^>$Y4V^(.^MW+"Y,ZD.I$>&7DBKCOFDSM>ZESFL9:I6.*A @Q+
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MMQ5K= /W0R+H$^UI?$TZHT[&'[
DM:V+ZNI+^RML.6%=?BN8I_EY'9/ADL
M!BP2:U[$YE>U^UF4]DQ)7JAB;?]E._?N#"^'A38J*1=#@T2F[G_^I?1#:\%B
M=,>"H%P06+W=1E;+%]SPIX]SM6,YO0UI=&%-M:NAG$PI*#
_H?4$L#!!0 ( ,QSHU)[%/#0>P( $,%
M 9 >&PO=V]R:W-H965T[#FR8\H=;&XU(6AEN\@(6E
M#5BO#/+&ULE5;;;MM&$/V5@9 '&V!$D93D2V4!
M=I*B 1K$2-(&1=&'%3D2%R&YS.[2LOOU/;.D6,5)C.1%W-N6=NJ]7>V$^N
M9/9T7U>-NYJ4WK>7<>SRDFOEIJ;E!CM;8VOE,;6[V+6651&,ZBI.9[-E7"O=
M3-:KL'9KURO3^4HW?&O)=76M[,,-5V9_-4DFAX5W>E=Z68C7JU;M^#W[/]I;
MBUD\HA2ZYL9ITY#E[=7D.KF\F
U*1E/0DR934N]Q45[0K=0U
M)'+T[J;6TNE[L;H7H2"1%8K6/78Y92IV>2D_DAO"A&4$6[M&E.XHJ[E]06FM
M,I91)JKEK%\@/\$*J;7-F),C#]V,? P7)*7WY#V+PF9D:3)",#H##W'IO$AL
MONXL&]DWF>SAA;WMF>2(XLCW*3( @FZ\U2J/\<*447XDEHHUMM_.ZI ]!^*G
M6CFH[T@VW_?(9LCHBC-9I]#$?%@TJO'0W>/1 PHX:*H%:JQC;$C^.0IVQ,6'
M4:MCE"IG\SJ#;(1W1/V*13& AF_*B.TI'S@NBY*